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Labeled
Off-Label
† Off-label indication
Per the manufacturer, this drug has been shown to be active against most strains of
the following microorganisms either in vitro and/or in clinical infections:
Entamoeba histolytica, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax.
NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not
been established in adequate and well-controlled clinical trials.
This drug may also have activity against the following microorganisms:
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this
list does not necessarily negate the drug’s activity against the organism.
INVESTIGATIONAL USE: For the treatment of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection†, the virus that causes coronavirus disease
2019 (COVID-19)†
amebiasis
malaria
malaria prophylaxis
coronavirus disease 2019 (COVID-19) †
discoid lupus erythematosus †
severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection †
Oral dosage
Adults weighing 50 kg or more
Available data are limited and efficacy has not been established. Due to a lack of clinical data, the
National Institutes of Health (NIH) COVID-19 treatment guidelines do not give recommendations for or
against the use of chloroquine; however, if used, guidelines advise monitoring for adverse events
including QT interval prolongation.[65314] 1,000 mg (600 mg base) PO on day 1 then 500 mg (300 mg
base) PO once daily for 4 to 7 days in patients in which enrollment in clinical trials is not feasible is
suggested by the FDA in the Emergency Use Authorization (EUA) statement.[65171] [65172] The NIH
recommends against the use of high-dose, twice daily chloroquine.[65314]
Adolescents weighing 50 kg or more
Available data are limited, and efficacy has not been established. Due to a lack of clinical data, the
National Institutes of Health (NIH) COVID-19 treatment guidelines do not give recommendations for or
against the use of chloroquine; however, if used, guidelines advise monitoring for adverse events
including QT interval prolongation.[65314] 1,000 mg (600 mg base) PO on day 1 then 500 mg (300 mg
base) PO once daily for 4 to 7 days in patients in which enrollment in clinical trials is not feasible is
suggested by the FDA in the Emergency Use Authorization (EUA) statement.[65171] [65172] The NIH
recommends against the use of high-dose, twice daily chloroquine.[65314]
For the treatment of uncomplicated malaria due to susceptible strains of P.
falciparum, P. knowlesi†, P. malariae, P. ovale, and P. vivax
Oral dosage
Adults
16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] PO once, then 8.3 mg (5 mg
base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO in 6 to 8 hours, then 8.3 mg (5 mg
base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once daily for 2 days.[29758] For P. vivax or
P. ovale, give in combination with primaquine phosphate or tafenoquine. Guidelines recommend
chloroquine for uncomplicated malaria in patients with chloroquine-sensitive P. falciparum or P. vivax or in
all patients with P. malariae, P. knowlesi, or P. ovale.[64059]
Infants, Children, and Adolescents
16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] PO once, then 8.3 mg (5 mg
base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO in 6 to 8 hours, then 8.3 mg (5 mg
base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once daily for 2 days.[29758] [63245] For P.
vivax or P. ovale, give in combination with primaquine phosphate or tafenoquine. Guidelines recommend
chloroquine for uncomplicated malaria in patients with chloroquine-sensitive P. falciparum or P. vivax or in
all patients with P. malariae, P. knowlesi, or P. ovale.[64059]
For malaria prophylaxis against chloroquine-sensitive Plasmodium species
Oral dosage
Adults
500 mg (300 mg base) PO weekly on the same day of each week, starting 2 weeks before entering the
endemic area and continuing for 8 weeks after leaving the area. If it is not feasible to begin therapy
before entering the endemic area, use 1,000 mg (600 mg base) as initial loading dose given in 2 divided
doses 6 hours apart.[29758] Alternatively, guidelines suggest a shorter course; start the usual dosage
regimen 1 to 2 weeks prior to entry into the endemic area and continue for 4 weeks after leaving the
area.[63990]
Pregnant Female Adults†
500 mg (300 mg base) PO weekly for duration of pregnancy for P. ovale or P. vivax infections after
completing acute treatment. After delivery, subsequent treatment with primaquine phosphate or
tafenoquine is needed in patients without G6PD deficiency.[64059]
Pregnant Female Adolescents†
500 mg (300 mg base) PO weekly for duration of pregnancy for P. ovale or P. vivax infections after
completing acute treatment. After delivery, subsequent treatment with primaquine phosphate or
tafenoquine (16 years and older) is needed in patients without G6PD deficiency.[64059]
Infants, Children, and Adolescents
8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO weekly on the same day of
each week, starting 2 weeks before entering the endemic area and continuing for 8 weeks after leaving
the area. If it is not feasible to begin therapy before entering the endemic area, use 16.6 mg (10 mg
base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] as initial loading dose given in 2 divided doses
6 hours apart.[29758] [63245] Alternatively, guidelines suggest a shorter course; start the usual dosage
regimen 1 to 2 weeks prior to entry into the endemic area and continue for 4 weeks after leaving the
area.[63245] [63990]
For the treatment of extraintestinal amebiasis (adjunct treatment with an effective
intestinal amebicide)
Oral dosage
Adults
1,000 mg (600 mg base) PO once daily for 2 days, then 500 mg (300 mg base) PO once daily for at least
2 to 3 weeks.[29758]
For the treatment of discoid lupus erythematosus†
Oral dosage
Adults
125 to 250 mg (75 to 150 mg base) PO once daily. Do not exceed 3.5 to 4 mg/kg/day to minimize retinal
toxicity. Chloroquine is recommended in patients who fail hydroxychloroquine plus quinacrine; quinacrine
may be continued with chloroquine.[62154]
Therapeutic Drug Monitoring
The following recommendations are for baseline and continuous monitoring when using chloroquine with
azithromycin:
Obtain a pre-treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG device.
Obtain baseline electrolytes, including calcium, magnesium, and potassium; correct abnormalities.
Determine if the patient is currently on any QT-prolonging medications that can be discontinued.
[65170]
Document high-risk cardiovascular and comorbid conditions.[65170] Assess and adjust for hepatic
and renal dysfunction.[65242]
 
Inpatient Use
Place telemetry prior to initiation, if possible.
Monitor and optimize serum electrolytes daily.[65242]
If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an
exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte
abnormalities, review and discontinue other unnecessary QTc prolonging medications, and proceed
with close QTc surveillance.[65170] Some experts recommend withholding treatment for patients with
a baseline QTc of 500 msec or more (or more than 530 to 550 msec in patients with a QRS interval
more than 120 msec) or in those with congenital long QT syndrome.[65242]
If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal males), or 480 to
499 msec (postpubertal females), correct contributing electrolyte abnormalities, review and
discontinue other unnecessary QTc prolonging medications, and obtain an initial on-therapy QTc
daily (or 48 and 96 hours after treatment initiation).[65170] [65242]
If the baseline QTc is less than 460 msec (prepubertal), less than 470 msec (postpubertal males), or
less than 480 msec (postpubertal females), correct electrolyte abnormalities and obtain an initial on-
therapy QTc daily (or 48 and 96 hours after treatment initiation).[65170] [65242]
Obtain an initial on-therapy QTc approximately 2 to 4 hours after the first dose and then daily (some
recommend 48 and 96 hours after treatment initiation).[65170] [65242]
Discontinue azithromycin and/or reduce the antimalarial dose if the subsequent QTc is prolonged or
significantly increased above the specified parameters. If the QTc remains prolonged or significantly
increased, reevaluate the risk/benefit of therapy, consider consultation with an electrophysiologist,
and consider hydroxychloroquine/chloroquine discontinuation.[65242]
 
Outpatient Use
Do not initiate outpatient therapy in the setting of acute renal or hepatic failure.[65242]
If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an
exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte
abnormalities, review and discontinue other unnecessary QTc prolonging medications, and proceed
with close QTc surveillance.[65170] Some experts recommend withholding treatment in patients with
a baseline QTc of 480 msec or more (or more than 510 to 530 msec in patients with a QRS interval
more than 120 msec), congenital long QT syndrome, or a Tisdale risk score of 11 or more.[65242]
Consider no further ECG/telemetry assessment for patients with a Tisdale risk score of 6 or less, if
resource or quarantine constraints are prohibitive of monitoring. Otherwise, repeat the ECT 2 to 3
hours after dosing on day 3 of therapy. If the QTc exceeds 500 msec (or 530 to 550 msec if QRS is
more than 120 msec) or increases by more than 30 to 60 msec, consider discontinuing therapy.[65242]
Maximum Dosage Limits
Adults
1,000 mg/dose (600 mg base/dose) PO for malaria up to a total of 2.5 g (1.5 g base) PO in 48 hours;
500 mg/week (300 mg base/week) PO for malaria prophylaxis; 1,000 mg/day (600 mg base/day) PO
for other indications.
Geriatric
1,000 mg/dose (600 mg base/dose) PO for malaria up to a total of 2.5 g (1.5 g base) PO in 48 hours;
500 mg/week (300 mg base/week) PO for malaria prophylaxis; 1,000 mg/day (600 mg base/day) PO
for other indications.
Adolescents
16.6 mg/kg/dose (10 mg base/kg/dose) [Max: 1,000 mg (600 mg base)] PO for malaria up to a total
of 41.5 mg/kg (25 mg/kg base) [Max: 2.5 g (1.5 g base)] PO in 48 hours; 8.3 mg/kg/week (5 mg
base/kg/week) [Max: 500 mg/week (300 mg base/week)] PO for malaria prophylaxis.
Children
16.6 mg/kg/dose (10 mg base/kg/dose) [Max: 1,000 mg (600 mg base)] PO for malaria up to a total
of 41.5 mg/kg (25 mg/kg base) [Max: 2.5 g (1.5 g base)] PO in 48 hours; 8.3 mg/kg/week (5 mg
base/kg/week) [Max: 500 mg/week (300 mg base/week)] PO for malaria prophylaxis.
Infants
16.6 mg/kg/dose (10 mg base/kg/dose) PO for malaria up to a total of 41.5 mg/kg (25 mg/kg base)
PO in 48 hours; 8.3 mg/kg/week (5 mg base/kg/week) PO for malaria prophylaxis.
Neonates
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
Chloroquine concentrates in the liver. However, no specific dosage adjustment guidelines are available for
patients with hepatic impairment.[29758]
Patients with Renal Impairment Dosing
CrCl 10 mL/minute or more: No dosage adjustment necessary.
CrCl less than 10 mL/minute: Decrease dose by 50%.[32569]
 
Intermittent hemodialysis:
Decrease dose by 50%.[32569]
 
Peritoneal dialysis:
Decrease dose by 50%.[32569]
 
Continuous renal replacement therapy:
No dosage adjustment necessary.[32569]
† Off-label indication
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How Supplied
Chloroquine Hydrochloride Solution for injection
Aralen 50mg/ml Solution for Injection (00024-0074) (Sanofi U.S. LLC) (off market)
Chloroquine Phosphate Oral tablet
Chloroquine Phosphate 250mg Tablet (76385-0142) (Bayshore
Pharmaceuticals LLC)
Chloroquine Phosphate Oral tablet
Chloroquine Phosphate 250mg Tablet (00143-1195) (Hikma Pharmaceuticals
USA inc.) (off market)
Chloroquine Phosphate 250mg Tablet (00143-1195) (Hikma Pharmaceuticals
USA Inc.) (off market)
Chloroquine Phosphate 250mg Tablet (00115-7056) (Impax Generics, a division of Impax Laboratories, Inc.) (off market)
Chloroquine Phosphate 250mg Tablet (00115-2790) (Impax Generics, a
division of Impax Laboratories, Inc.) (off market)
Chloroquine Phosphate 250mg Tablet (64980-0177) (Rising Pharmaceuticals
Inc)
Chloroquine Phosphate 250mg Tablet (64980-0177) (Rising Pharmaceuticals
Inc) (off market)
Chloroquine Phosphate 250mg Tablet (63304-0460) (Sun Pharmaceutical
Industries, Inc.) (off market)
Aralen 500mg Tablet (00280-0084) (Bayer Corp Consumer Care Div) (off market)
Aralen 500mg Tablet (00024-0084) (Sanofi U.S. LLC) (off market)
Chloroquine Phosphate Oral tablet
Chloroquine Phosphate 500mg Tablet (00143-2125) (Hikma Pharmaceuticals
USA Inc.) (off market)
Chloroquine Phosphate 500mg Tablet (00115-7010) (Impax Generics, a
division of Impax Laboratories, Inc.) (off market)
Chloroquine Phosphate 500mg Tablet (43063-0454) (PD-Rx Pharmaceuticals, Inc.)
Chloroquine Phosphate 500mg Tablet (55289-0856) (PD-Rx
Pharmaceuticals, Inc.)
Chloroquine Phosphate 500mg Tablet (64980-0178) (Rising Pharmaceuticals Inc) (off market)
Chloroquine Phosphate 500mg Tablet (64980-0178) (Rising Pharmaceuticals Inc)
Chloroquine Phosphate 500mg Tablet (63304-0461) (Sun Pharmaceutical Industries, Inc.) (off market)
Description/Classification
Description
Chloroquine is a 4-aminoquinoline anti-protozoal agent indicated for the treatment and prophylaxis of
susceptible malaria strains and for the treatment of extraintestinal amebiasis. Chloroquine is not active against
gametocytes and the exoerythrocytic forms including the hypnozoite stage of the Plasmodium parasites.
Resistance to chloroquine is widespread. Irreversible retinal damage has been observed with use, and
postmarketing cases of life-threatening and fatal cardiomyopathy, including ventricular arrhythmias and torsade
de pointes (TdP), have been reported.[29758]
 
Updates for coronavirus disease 2019 (COVID-19):
Available data are limited. Due to a lack of clinical data, the National Institutes of Health (NIH) COVID-19
treatment guidelines do not give recommendations for or against the use of chloroquine; however, if used,
guidelines advise monitoring for adverse events including QT interval prolongation.[65314] The FDA has issued
an Emergency Use Authorization (EUA) for the use of chloroquine to treat hospitalized COVID-19 patients for
whom clinical trial participation is not feasible.[65171][65172] Use in COVID-19 patients outside of clinical trials
or in a nonhospital setting is not recommended due to the potential for serious adverse events and drug
interactions.[65332] The NIH recommends against the use of high-dose, twice daily chloroquine.[65314]
Preliminary data suggest chloroquine may have clinical benefit in the treatment of COVID-19 due to SARS-
CoV-2. In results for more than 100 patients, chloroquine was superior to control in inhibiting the exacerbation
of pneumonia.[65119][65124][65126] In a parallel, double-masked, randomized clinical trial (n = 81), two doses of
chloroquine were analyzed. The high-dose group had a higher incidence of QT interval greater than 500
milliseconds (18.9%) compared with the low-dose group (11.1%); therefore, the study was unmasked and all
patients were reverted to the low-dose group. Respiratory secretions on day 4 were negative in 22.2% of patients
(6 of 27 patients analyzed).[65333] Additional data regarding clinical efficacy for COVID-19 are being
evaluated.[65123]
Classifications
General Anti-infectives Systemic
Antiparasitic Agents, Insecticides, and Repellants
Antiprotozoals
Agents for Amoebiasis and Other Protozoal Diseases
Antimalarials
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Oral Administration
May administer with meals in patients who experience gastrointestinal side effects.[63990]
Oral Solid Formulations
To mitigate bitter tablet taste for children, tablets may be pulverized and enclosed in gelatin capsules.
If the child is unable to swallow the capsules or tablets, the gelatin capsules may be opened and the
contents mixed with a small amount of something sweet, such as applesauce, chocolate syrup, or
jelly.[63990]
Extemporaneous Compounding-Oral
NOTE: Chloroquine extemporaneous suspension is not FDA-approved.
Extemporaneous chloroquine suspension has been compounded using the following formulations:
Chloroquine phosphate 15 mg/mL in 1:1 Ora-Sweet and Ora-Plus, 1:1 Ora-Sweet SF and Ora-Plus,
or Cherry Syrup:
Pulverize three 500-mg chloroquine phosphate tablets into a fine powder in a mortar.
Add approximately 15 mL of vehicle, which may be a 1:1 mixture of Ora-Sweet and Ora-
Plus, 1:1 mixture of Ora-Sweet SF and Ora-Plus, or cherry syrup.
Add the vehicle in geometric portions almost to volume and mix thoroughly after each
addition.
Transfer the contents of the mortar to a calibrated bottle.
Add enough vehicle to bring the final volume to 100 mL.
Label "Shake Well Before Using" and "Protect from Light"
Storage: The suspension is stable for 60 days when stored without light at 5 and 25
degrees C.[62145]
Chloroquine base 10 mg/mL in Cherry Syrup:
Pulverize two 500-mg chloroquine phosphate tablets in a mortar after removing the film
coating.
Levigate with a small amount of sterile water.
Add by geometric proportions a significant amount of cherry syrup, and levigate until a
uniform mixture is obtained.
Transfer the contents of the mortar to a conical graduated cylinder.
Add enough cherry syrup to bring the final volume to 60 mL.
Pour the suspension into an amber glass bottle and shake vigorously.
Storage: The suspension is stable for up to 4 weeks under refrigeration (4 degrees C), at
room temperature (22 to 25 degrees C), and at 29 degrees C.[62150]
Chloroquine base 15 mg/mL in Glycerin or Distilled Water, Cologel (Lilly), and Simple
Syrup/Cherry Syrup:
Pulverize two 500-mg chloroquine phosphate tablets in a mortar.
Levigate with a small amount of glycerin or distilled water.
Add 13 mL of Cologel, and levigate until a uniform mixture is obtained.
Add by geometric proportion a significant amount of a 2:1 simple syrup/cherry syrup
mixture, and levigate until a uniform mixture is obtained.
Transfer the contents of the mortar to a conical graduated cylinder.
Add enough of the syrup mixture to bring the final volume to 40 mL.
Pour the suspension into an amber glass bottle and shake vigorously.
Label "Shake Well" and "Refrigerate".
Storage: The suspension is stable for 3 days when stored in the refrigerator.[62172]
Clinical Pharmaceutics Information
From Trissel's 2™ Clinical Pharmaceutics Database  
Chloroquine
1. pH Range
pH 5.5 to 6.6 (as the hydrochloride salt)
References
McEvoy GK (ed). AHFS Drug Information (current edition). Bethesda, MD: American Society of
Health-System Pharmacists.
2. Stability
Chloroquine sulfate in intact containers stored as directed by the manufacturer is stable until the
labeled expiration date. Infusion Solutions: Chloroquine sulfate 0.5 mg/mL in sodium chloride 0.9%
was reported by Martens et al. to be stable for 24 hours at 21 degree C protected from exposure to
light.
References
Anon. Manufacturer's information and labeling. (Package insert).
Martens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass,
and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47:369-73
3. Light Exposure
Chloroquine injection should be protected from exposure to light during long-term storage.
References
Anon. Manufacturer's information and labeling. (Package insert).
Anon. BIAM; l'Universite et l'Industrie Pharmaceutique, Banque de donnes automatisee surles
medicaments (Biam), Paris, France. Accessed at: http://www2.biam2.org.
Anon. South African Electronic Package Inserts, Malahyde Information Systems. Accessed at
http://home.intekom.com/pharm/intramed.
4. Filtration
Geary et al. reported that chloroquine exhibited binding to cellulose acetate filters. About 60% or
more of the drug was lost from 10 mL of a chloroquine 0.32-mg/mL solution passed through
Millipore and Nalgene 0.45-micron cellulose acetate filters. No drug loss occurred when the
chloroquine solution was passed through a polycarbonate filter. The clinical implications, if any, of
binding to filters from such a low concentration are uncertain.
References
Geary TG, Akood MA, Jensen JB. Characteristics of chloroquine binding to glass and plastic. Am J
Trop Med Hyg. 1984; 32:19-23
5. Sorption Leaching
Geary et al. reported that chloroquine at low concentrations exhibits sorption to glass. As much as 30
to 40% was lost to glass test tubes from a 0.32 mg/mL solution. No loss due to sorption to
polycarbonate, polystyrene, or polypropylene plastics was found. The clinical implications, if any, of
sorption from such a low concentration are uncertain. Moreover, Martens et al. were unable to
confirm this result. They found no sorption to glass bottles, polyvinyl chloride (PVC) plastic bags,
and polyethylene-lined laminated bags from a chloroquine 0.5 mg/mL (as sulfate) solution.
References
D'Arcy PF. Drug interactions with medical plastics. Drug Intell Clin Pharm. 1083; 17:726-31
Geary TG, Akood MA, Jensen JB. Characteristics of chloroquine binding to glass and plastic. Am J
Trop Med Hyg. 1984; 32:19-23
Martens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass,
and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47:369-73
6. Stability Max
Maximum reported stability period: In NS- 24 hours at room temperature
References
Martens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass,
and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47:369-73
Compounding Drug Information
From Trissel's 2™ Clinical Pharmaceutics Database  
Chloroquine
1. Identity/Properties
Chloroquine is a white to slightly yellow, odorless crystalline powder with a bitter taste. The
hydrochloride, a white crystalline substance, is prepared using hydrochloric acid. Chloroquine
hydrochloride 123 mg is approximately equivalent to 100 mg of chloroquine. The phosphate is a
white or almost white, odorless, hygroscopic crystalline powder with a bitter taste. Chloroquine
phosphate 161 mg is approximately equivalent to 100 mg of chloroquine. Solubility: Chloroquine is
only slightly soluble in water. The hydrochloride and the phosphate are freely soluble in water. The
phosphate has an aqueous solubility of about 250 mg/mL but is almost insoluble in ethanol. pH:
Chloroquine hydrochloride injection has a pH between 5.5 and 6.5. A 1% chloroquine phosphate
solution has a pH of about 4.5.
References
Anon. Manufacturer's information and labeling. (Package insert and bulk material data sheet).
Anon. The Merck Index, Whitehouse Station, New Jersey: Merck & Co., Inc. Current edition.
Anon. Martindale The Complete Drug Reference. London: The Pharmaceutical Press. Current edition
and selected information from prior editions.
Anon. The United States Pharmacopeia. Rockville, Maryland: The United States Pharmacopeial
Convention. Current edition.
McEvoy GK (ed). AHFS Drug Information (current edition). Bethesda, MD: American Society of
Health-System Pharmacists.
2. General Stability Info
Chloroquine products should be stored in well-closed containers. The injection (as the hydrochloride)
should be stored at controlled room temperature and protected from freezing and temperatures
exceeding 40degree C. The phosphate is light sensitive, discoloring upon light exposure.
References
Anon. Martindale The Complete Drug Reference. London: The Pharmaceutical Press. Current edition
and selected information from prior editions.
Anon. The United States Pharmacopeia. Rockville, Maryland: The United States Pharmacopeial
Convention. Current edition.
McEvoy GK (ed). AHFS Drug Information (current edition). Bethesda, MD: American Society of
Health-System Pharmacists.
3. Injection, extemporaneous
Injections, like other sterile drugs, should be prepared in a suitable clean air environment using
appropriate aseptic procedures. When prepared from non-sterile components, an appropriate and
effective sterilization method must be employed. Allen reported on a compounded formulation of
chloroquine phosphate 64.5-mg/mL injection. The injection had the following formula: Chloroquine
phosphate- 6.45 g Benzyl alcohol- 2 g Sterile water for injection- qs 100 mL The recommended
method of preparation is to dissolve the chloroquine phosphate powder in about 90 mL of sterile
water for injection. The benzyl alcohol is then added and stirred until dissolved. Sterile water for
injection sufficient to bring the volume to 100 mL is added and the solution is mixed well. The
solution is to be filtered through a suitable 0.2-micron sterilizing filter and packaged in sterile
containers. If no sterility test is performed, the USP specifies a beyond-use date of 24 hours at room
temperature or three days stored under refrigeration because of concern for inadvertent
microbiological contamination during preparation. However, if an official USP sterility test for each
batch of drug is performed, the author recommended a beyond-use date of six months at room
temperature because this formula is similar or the same as a commercial medication in some
countries with an expiration date of two years or more.
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4. Oral Liquid
Study 1: Closson reported that chloroquine hydrochloride injection (Aralen HCl, Sanofi Winthrop)
was added to simple syrup to make a 20-mg/mL oral pediatric dosage form. The product was
incubated at 49degree C for 63 hours; no visible changes in physical appearance or consistency
occurred. The product then was frozen at -6degree C for eight hours; it became a white frozen solid
and reliquified upon warming to its original colorless, slightly hazy appearance. No chemical analysis
was performed. Study 2: Allen and Erickson evaluated the stability of three chloroquine phosphate
15-mg/mL oral liquids extemporaneously compounded from tablets. Vehicles used in this study were
(1) an equal parts mixture of Ora-Sweet and Ora-Plus (Paddock), (2) an equal parts mixture of Ora-
Sweet SF and Ora-Plus (Paddock), and (3) cherry syrup (Robinson Laboratories) mixed 1:4 with
simple syrup. Three chloroquine phosphate 500-mg tablets (Sanofi Winthrop) were crushed and
comminuted to fine powder using a mortar and pestle. About 15 mL of the test vehicle was added to
the powder and mixed to yield a uniform paste. Additional vehicle was added geo-metrically and
brought to the final volume of 100 mL, mixing thoroughly after each addition. The process was
repeated for each of the three test suspension vehicles. Samples of each of the finished suspensions
were packaged in 120-mL amber poly-ethylene terephthalate plastic prescription bottles and stored at
5degree C and 25degree C. Because the phosphate salt is freely soluble in water, the drug is in
solution in these products. No visual changes or changes in odor were detected during the study.
Stability-indicating HPLC analysis found little or no drug loss in any of the liquid products stored at
either temperature after 60 days of storage. Study 3: Odusote and Nasipuri evaluated the stability of
three syrup formulations (See Table 1 below) containing chloroquine phosphate 16 mg/mL prepared
from bulk powder. The sucrose syrup formulation was prepared by adding the chloroquine phosphate
powder and sodium benzoate to heated syrup and stirring until complete dissolution occurred. The
flavor and color were then added. The other two formulations were prepared by dispersing the
methylcellulose in some hot water followed by ice-cold water and subsequently keeping the mixture
in a freezer. The other materials then were added and mixed well. After preparation, the syrups were
packaged in amber bottles and stored at 5, 25, and 40degree C for 12 weeks. Chloroquine content
was assessed spectrophotometrically. No change in chloroquine concentration and no observable
physical change were found in samples from any storage temperature during storage. If clear bottles
were used instead of amber, exposure to light resulted in about 6% drug loss in eight weeks. If the
syrup pH was adjusted from the original pH 4.5 to 4.9 down to pH 3.5 with citric acid (used to help
mask the bitter taste), the chloroquine concentration remained constant over 12 weeks at all
temperatures. However, if 1% sodium carboxymethylcellulose was substituted as the viscosity agent,
a white turbidity or precipitate appeared (depending on concentration) along with a sudden drop in
viscosity, indicating an interaction with the chloroquine phosphate. Consequently, Odusote and
Nasipuri recommended using only methylcellulose as the viscosity-imparting agent. Table 1.
Chloroquine Phosphate Formulations Tested for Stability by Odusote and Nasipuri Formula 1:
Chloroquine phosphate 1.6 g Sodium benzoate 0.2 g Essence of lemon grass 0.5 mL Yellow food
color 0.2 mL Sucrose syrup 84% (w/v) qs 100mL Formula 2: Chloroquine phosphate 1.6 g Sodium
benzoate 0.2 g Saccharin sodium 0.05 g Essence of lemon grass 0.5 mL Yellow food color 0.2 mL
Methylcellulose 1.12% solution qs 100 mL Formula 3: Chloroquine phosphate 1.6 g Sodium
benzoate 0.2 g Talin 0.05 g Essence of lemon grass 0.5 mL Yellow food color 0.2 mL
Methylcellulose 1.12% solution qs 100 mL Study 4: Mirochnick et al. attempted to determine the
stability of a chloroquine phosphate suspension prepared from tablets. Although no loss of drug was
found by HPLC analysis, substantial increases in drug concentration at various time points indicated
a nonuniform dispersion of the drug might have existed. Study 5: Van Doorne et al. evaluated the
suitability of several antimicrobial preservatives for use in chloroquine phosphate 16-mg/mL syrup
containing sucrose 66%. Chloroform had been used previously, but it is carcinogenic, potentially
toxic to liver and kidneys, and is volatile resulting in loss of protection over time. Benzalkonium
chloride is unsuitable because of its taste and incompatibilities. The best result was obtained using
sorbic acid 1.5 g/L along with citric acid 2 g/L to reduce the pH to 4. Methylparaben 1.8 g/L with
propylparaben 0.2 g/L also was acceptable, although the latter system was not as effective against
Aspergillus niger. Study 6: Chandibhamar et al. evaluated the stability of a taste-masked suspension
of chloroquine. Chloroquine phosphate 1.7 g was dissolved in 40 mL of simple syrup containing
glycerin 5% (v/v). Then 30 mL of hot syrup containing pamoate sodium 1.3 g and sodium
bicarbonate 0.56 g was slowly mixed in at a rate of 5 mL per minute with constant stirring of 30 to 80
RPM. A precipitate of chloroquine pamoate was produced. The suspension was adjusted to pH 6.0
and sodium benzoate 100 mg, amaranth, and raspberry flavor were added. The suspension was
brought to 100 mL with additional syrup. The suspension exhibited a very slow rate of sedimentation.
Spectroscopic analysis found the suspension remained stable over at least 42 days at 25 degree C
with over 98% of the ion pair remaining and only 1.75% of free chloroquine present. Elevated
temperature of 45 degree C resulted in an approximate doubling of the rate of free chloroquine
formation. Bioavailability of this suspension was comparable with chloroquine phosphate liquid.
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5. Topical
Brouwers et al. developed a topical gel containing chloroquine phosphate for use as a microbicide
against HIV-1 infection. The gel was prepared by adding a mixture of hydroxyethyl cellulose 1.6%
wt/wt and glycerol 2.5% to a solution of methyl- and propylparabens 0.18% and 0.02%, respectively.
When mixed, a clear and homogeneous gel formed. The pH of the gel was decreased by adding lactic
acid 0.05% and adjusting to pH 4.5 by adding sodium hydroxide 1 M. Chloroquine phosphate
powder was added to the gel in varying amounts of 0.3, 1.3, 3, 10, and 30 mg/g of gel and mixed
thoroughly to assure complete dissolution and uniformity. Entrapped air was removed by using
reduced pressure. The completed gels were packaged in capped syringes. The gels were clear and
homogeneous with an osmolality of 300 mOsm/kg, a pH of 4.6, and a viscosity of 1.4 Pa s. Samples
containing chloroquine phosphate 3 mg/g were stored at 40degree C and 75% relative humidity for
three months. Little or no change in gel mass, pH, and osmolality occurred. Viscosity decreased by
14%, which is similar to changes observed in previously reported observations for hydroxyethyl
cellulose gels. HPLC analysis found that little or no change in chloroquine concentrations occurred
over the three-month test period.
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Adverse Reactions
Irreversible maculopathy and macular degeneration have been reported with chloroquine or other 4-
aminoquinoline compounds during postmarketing use. Irreversible retinopathy with retinal pigment changes
(bull's eye appearance) and visual field defects (paracentral scotomas) have been reported in patients receiving
long-term or high-dose 4-aminoquinoline therapy. Visual impairment (i.e., blurred vision and difficulty in
focusing or accommodation), nyctalopia (night blindness), scotomatous vision with field defects of paracentral,
pericentral ring types, and typically temporal scotomata (e.g., difficulty in reading with words tending to
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disappear, seeing half an object, misty vision, and fog before the eyes), and reversible corneal opacification
(corneal deposits) have been reported. For patients with significant risk factors, monitoring should include
annual examinations which include best corrected distance visual acuity (BCVA), automated threshold visual
field (VF), and spectral domain optical coherence tomography (SD-OCT). For individuals without significant
risk factors, annual exams can usually be deferred until 5 years of treatment. Discontinue chloroquine if ocular
toxicity is suspected, and monitor the patient closely as retinal changes and visual disturbances may progress
after cessation of therapy.[29758]
Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis,
pleomorphic skin eruptions, skin and mucosal pigmentary changes (skin discoloration), lichen planus-like
eruptions, pruritus, drug reaction with eosinophilia and systemic symptoms (DRESS), photosensitivity, hair loss
(alopecia), bleaching of hair pigment (hair discoloration), urticaria, anaphylactoid reactions or anaphylactic
shock, and angioedema have been reported during postmarketing use of chloroquine or other 4-aminoquinoline
compounds. An acute attack of psoriasis can be precipitated by chloroquine in predisposed patients.[29758]
Chloroquine has been associated with acute generalized exanthematous pustulosis (AGEP). The non-follicular,
pustular, erythematous rash starts suddenly and is associated with fever above 38 degrees C. Drugs are the main
cause of AGEP. A period of 2 to 3 weeks after an inciting drug exposure appears necessary for a first episode of
AGEP. Unintentional reexposure may cause a second episode within 2 days.[27736]
Hematological adverse reactions have been reported during postmarketing use of chloroquine or other 4-
aminoquinoline compounds and include reversible agranulocytosis, aplastic anemia, pancytopenia, neutropenia,
and thrombocytopenia. Chloroquine may cause hemolysis and hemolytic anemia in patients with glucose-6-
phosphate dehydrogenase deficiency (G6PD deficiency).[29758]
During postmarketing use, chloroquine and/or other 4-aminoquinoline compounds have been associated with
sensorimotor disorders as well as skeletal muscle myopathy or neuromyopathy leading to progressive weakness
(myasthenia) and atrophy of proximal muscle groups, depressed tendon reflexes (hyporeflexia), and abnormal
nerve conduction. Periodically test knee and ankle reflexes to detect any evidence of muscular weakness.
Discontinue chloroquine if weakness develops.[29758]
Nerve type deafness, tinnitus, and reduced hearing (hearing loss) in patients with preexisting auditory damage
have been reported during postmarketing use of chloroquine or other 4-aminoquinoline compounds. Discontinue
chloroquine with any hearing defects, and monitor the patient closely.[29758]
Cardiovascular adverse reactions associated with chloroquine or other 4-aminoquinoline compounds during
postmarketing include cardiomyopathy (which may result in cardiac failure and in some cases fatal outcome),
electrocardiogram (ECG) changes (particularly, inversion or flattening of the T-wave with widening of the QRS
complex), and hypotension. Cardiac arrhythmias, conduction disorders such as bundle-branch block and AV
block, QT prolongation, torsade de pointes (TdP), ventricular arrhythmias (e.g., ventricular tachycardia,
ventricular fibrillation) have been reported, including fatal cases. The risk is greater with higher doses, although
cases have been reported with therapeutic doses. Chronic toxicity should be considered when conduction
disorders, such as bundle-branch block or AV block, are diagnosed. Additionally, cases of cardiomyopathy
resulting in cardiac failure with some cases of fatal outcome have been reported with chloroquine. Prompt
discontinuation of chloroquine may prevent life-threatening complications if cardiotoxicity is suspected.[28225] 
[28229] [28230] [28231] [29758]
Adverse gastrointestinal effects noted with chloroquine or other 4-aminoquinoline compounds during
postmarketing include hepatitis, elevated hepatic enzymes, nausea, vomiting, abdominal pain/cramps, diarrhea,
and anorexia.[29758] Gastric effects can be minimized by taking chloroquine with food.[61673]
Nervous system adverse reactions associated with chloroquine or other 4-aminoquinoline compounds during
postmarketing include headache (usually mild and transient), seizures, polyneuropathy, acute extrapyramidal
symptoms (e.g., dystonia, dyskinesia, tongue protrusion, torticollis), and neuropsychiatric changes including
psychosis, delirium, anxiety, agitation, insomnia, hallucinations, confusion, personality changes, depression, and
suicidal ideation/behavior. Extrapyramidal symptoms usually resolve after treatment discontinuation and/or
symptomatic treatment.[29758]
Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life
threatening in patients treated with or without antidiabetic medications. Monitor blood glucose and adjust
treatment as necessary in patients presenting with clinical symptoms of hypoglycemia during chloroquine
treatment.[29758]
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Contraindications/Precautions
Absolute contraindications are italicized.
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Chloroquine is reported in the literature to be a weak genotoxic agent that may elicit both gene mutations and
chromosomal/DNA breaks. Mechanisms may involve DNA intercalation or induction of oxidative stress. Both
positive and negative results have been reported with in vitro reverse gene mutation assays and with in vivo
animal studies. The chromosomal effects were not observed when chloroquine was administered to animals
orally.[29758]
Antimicrobial resistance to chloroquine therapy is widespread in P. falciparum and is reported in P. vivax. Prior
to chloroquine use, it should be ascertained whether chloroquine is appropriate for use based on resistance
patterns. Information regarding the geographic areas where resistance to chloroquine occurs is available from the
Centers for Disease Control and Prevention.[29758]
Use of chloroquine for indications other than acute malaria is contraindicated in patients with ocular disease,
specifically those who have retinal or visual field changes of any etiology. Irreversible retinal damage has been
observed in some patients who received chloroquine. Significant risk factors for retinal damage include daily
doses of chloroquine phosphate more than 2.3 mg/kg of actual body weight, duration of use more than 5 years,
subnormal glomerular filtration (renal impairment or renal failure), use of some concomitant drug products such
as tamoxifen, and concurrent macular disease. Baseline ophthalmological examination should be performed
within the first year of starting chloroquine and should include best corrected distance visual acuity (BCVA),
automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and
spectral domain optical coherence tomography (SD-OCT). In Asian patients, retinal toxicity may first be noticed
outside the macula, and VF testing should be performed in the central 24 degrees instead of the central 10
degrees. For patients with significant risk factors, monitoring should include annual examinations which include
BCVA, VF, and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred
until 5 years of treatment. Discontinue chloroquine if ocular toxicity is suspected, and monitor the patient
closely as retinal changes and visual disturbances may progress after cessation of therapy.[29758] The use of
chloroquine should be approached with caution in patients with Fabry disease, particularly those with ocular
symptoms. The drug can cause a keratopathy that is clinically and ultrastructurally indistinguishable from
keratopathy caused by Fabry disease; this drug-induced keratopathy is reversible with drug cessation. In
addition, chloroquine poses a theoretical risk of decreased intracellular alpha-galactosidase A activity in Fabry
disease patients. Chloroquine has been reported to induce clinical symptoms that mimic those of Fabry disease,
including formation of inclusion bodies that are biochemically and ultrastructurally similar in most of the cells
affected by Fabry disease (e.g., striated muscle, smooth muscle, etc.). The distinguishing factor is that the
ultrastructural features of chloroquine toxicity in striated muscle, curvilinear bodies, are not present in renal
cells.[30609]
Chloroquine is contraindicated in patients with known chloroquine hypersensitivity, or with a known allergy to
4-aminoquinolines. Patients with hydroxychloroquine hypersensitivity may have cross sensitivity to
chloroquine.[29758]
QT prolongation, torsade de pointes (TdP), and ventricular arrhythmias have been reported with chloroquine
use. The risk is greater with higher doses, although cases have been reported with therapeutic doses.[28225] 
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[28229] [28230] [28231] [29758] Use chloroquine with caution in patients with conditions that may increase the risk
of QT prolongation including congenital long QT syndrome, bradycardia, AV block, heart failure, stress-related
cardiomyopathy, myocardial infarction, stroke, hypomagnesemia, hypokalemia, hypocalcemia, or in patients
receiving medications known to prolong the QT interval or cause electrolyte imbalances. Females, geriatric
patients, patients with sleep deprivation, pheochromocytoma, sickle cell disease, hypothyroidism,
hyperparathyroidism, hypothermia, systemic inflammation (e.g., human immunodeficiency virus (HIV)
infection, fever, and some autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus
(SLE), and celiac disease) and patients undergoing apheresis procedures (e.g., plasmapheresis [plasma
exchange], cytapheresis) may also be at increased risk for QT prolongation.[28432] [28457] [29758] [56592] [65180]
In patients taking chloroquine with another drug that also prolongs the QT interval (see Therapeutic Drug
Monitoring for recommendations specific to azithromycin with chloroquine used together for COVID-19),
obtain a pre-treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG device. Obtain baseline
electrolytes, including calcium, magnesium, and potassium. Determine if the patient is currently on any QT-
prolonging medications that can be discontinued. Document high-risk cardiovascular and comorbid conditions.
If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an exaggerated
QTc response (i.e., change of 60 msec or more), correct contributing electrolyte abnormalities, review and
discontinue other unnecessary QTc prolonging medications, and proceed with close QTc surveillance. Obtain an
initial on-therapy QTc approximately 2 to 4 hours after the first dose and then again at 48 and 96 hours after
treatment initiation. If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal males),
or 480 to 499 msec (postpubertal females), correct contributing electrolyte abnormalities, review and discontinue
other unnecessary QTc prolonging medications, and obtain an initial on-therapy QTc 48 and 96 hours after
treatment initiation. If the baseline QTc is less than 460 msec (prepubertal), less than 470 msec (postpubertal
males), or less than 480 msec (postpuberal females), correct electrolyte abnormalities and obtain an initial on-
therapy QTc 48 and 96 hours after treatment initiation.[65170] Consider chronic chloroquine toxicity when
conduction disorders, such as bundle-branch block or AV block, are diagnosed. Cases of cardiomyopathy
resulting in cardiac failure, sometimes fatal, have been reported with chloroquine. Prompt discontinuation of
chloroquine may prevent life-threatening complications if cardiotoxicity is suspected.[29758]
Chloroquine should not be used in patients with psoriasis unless the benefit to the patient outweighs the potential
risks because it may precipitate a severe attack of psoriasis.[29758]
Chloroquine should be used with caution in patients with hepatic disease or alcoholism because the drug is
metabolized in the liver and accumulation can occur producing toxic effects. Patients receiving other hepatotoxic
drugs also should be treated with caution.[29758]
Chloroquine should be used with caution in patients with neurological disease including preexisting hearing
impairment or seizure disorder. Polyneuritis, ototoxicity, seizures, neuromyopathy, and acute extrapyramidal
symptoms (dystonia, dyskinesia, tongue protrusion, torticollis) have occurred with chloroquine therapy.
Symptoms of muscle weakness and response of knee and ankle reflexes should be investigated regularly. If
muscle weakness, extrapyramidal symptoms, or any defects in hearing occur during chloroquine therapy, the
drug should be discontinued immediately and the patient observed closely.[29758]
Chloroquine can exacerbate porphyria or may cause hemolysis in patients with glucose-6-phosphate
dehydrogenase deficiency (G6PD deficiency). Use chloroquine with caution in patients with these conditions.
Blood monitoring for hemolytic anemia in G6PD deficiency patients may be necessary, particularly with
concomitant use of other medications associated with hemolysis.[29758]
Use chloroquine with caution in patients with hypoglycemia or diabetes mellitus. Chloroquine can cause severe,
life-threatening hypoglycemia in patients with or without antidiabetic medications. Warn patients about the risk
of hypoglycemia and the associated clinical signs and symptoms. Monitor blood glucose and adjust treatment as
necessary in patients presenting with clinical symptoms of hypoglycemia during chloroquine treatment.[29758]
Children are especially sensitive to the 4-aminoquinoline compounds. Fatalities have been reported after
accidental exposure of chloroquine; some cases involved relatively small doses (e.g., 0.75 g or 1 g in a 3-year-
old child). Strongly warn patients to keep chloroquine out of the reach of pediatric patients, including neonates,
infants, children, and adolescents.[29758]
Weigh the benefit of chloroquine prophylaxis or treatment of malaria against the potential risk to the fetus, and
consider the drug's potential to remain in the body for several months after discontinuation of therapy.[29758] 
[63990] [64059] In humans at recommended doses for prophylaxis and treatment of malaria, observational studies
as well as a meta-analysis, including a small number of prospective studies with chloroquine during pregnancy,
have shown no increase in the rate of birth defects or spontaneous abortions.[29758] Guidelines recommend
chloroquine as a treatment option for acute malaria and for prophylaxis in pregnant women during all trimesters.
Chloroquine crosses the placenta, but the potential damage to the mother from malaria is greater than the drug's
risk to the fetus. Weekly prophylactic doses appear to have minimal adverse effects when administered during
pregnancy.[63990] [64059] Animal studies showed embryo-fetal developmental toxicity at doses 3 to 16 times the
maximum recommended therapeutic dose and the potential of genotoxicity in some test systems.
Autoradiographic studies have shown accumulation in the eyes and ears when chloroquine is administered at the
start or end of gestation in animal studies.[29758]
Use caution when administering chloroquine to breast-feeding women. Chloroquine is excreted into breast milk.
The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in
11 lactating mothers following a single oral dose of chloroquine (600 mg base).The maximum daily dose of the
drug that the infant received from breast-feeding was about 0.7% of the maternal start dose of the drug in
malaria chemotherapy. Separate chemoprophylaxis for an infant is required.[29758] However, previous American
Academy of Pediatrics (AAP) recommendations consider chloroquine usually compatible with breast-feeding,
and chloroquine has an established dosage in infants.[27500]
Chloroquine should be used with caution in males because animal studies suggest that infertility is possible;
after 30 days of oral treatment, testosterone levels and weight of testes, epididymis, seminal vesicles, and
prostate decreased.[29758]
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65170 – Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and
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[published online ahead of print, March 25, 2020]. Mayo Clin Proc 2020;95.
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Mechanism of Action
Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism is unknown. Chloroquine
may exert its effect against Plasmodium species by concentrating in the acid vesicles of the parasite and by
inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. Chloroquine
is not active against gametocytes and the exoerythrocytic forms, including the hypnozoite stage (P. vivax and P.
ovale) of the Plasmodium parasites. Organisms with reduced susceptibilities to hydroxychloroquine also show
reduced susceptibilities to chloroquine.[29758]
 
Although the mechanisms underlying the antiinflammatory and immunomodulatory effects of chloroquine are
unknown, several possible mechanisms of action have been proposed. It is unclear if these mechanisms work
similarly for rheumatic and autoimmune diseases. Potential mechanisms include reduced cytokine production,
inhibition of immune effector cells, inhibition of platelet function, protection of the cell surface from external
disturbances, competitive binding to nucleic acid ligands or toll-like receptors (TLRs), interference with
lysosomal function, reduction of leakage of lysosomal enzymes, and interference with endosomal NADPH
oxidase (NOX).[61727] [61728] [61729]
 
There are several potential mechanisms by which chloroquine may be active against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). These include inhibition of viral enzymes or processes such as viral
DNA and RNA polymerase, viral protein glycosylation, virus assembly, new virus particle transport, and virus
release. Other mechanisms may also involve ACE2 cellular receptor inhibition, acidification at the surface of the
cell membrane inhibiting fusion of the virus, and immunomodulation of cytokine release.[61729] [61732] [65120] 
[65121] [65139] [65140] [65141] [65142] [65143]
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Pharmacokinetics
Chloroquine is administered orally. It is widely distributed into body tissues, with higher concentrations in the
liver, kidneys, spleen, and lungs. Leukocytes also concentrate the drug. Smaller amounts of the drug are found in
the brain and spinal cord. Cells containing melanin in the eyes and skin bind strongly to chloroquine. The drug
also concentrates in erythrocytes and is bound to platelets and granulocytes. It is about 55% bound to plasma
protein.[29758] [61731] [62151]
 
Excretion of chloroquine is largely through urine, but this is a slow process and may be increased by
acidification of the urine. Chloroquine undergoes appreciable degradation in the body, and the major metabolite
is desethylchloroquine. Slightly more than half of a dose is excreted in urine as unchanged drug and about 25%
as the major metabolite; bisdesethylchloroquine and other metabolic products are found in small amounts. A
small portion of the unabsorbed drug is excreted in the feces. Elimination appears to take place in a biphasic
manner. The elimination half-life is 108 to 291 hours.[29758] [61731] [62151]
 
Affected cytochrome P450 isoenzymes and drug transporters: CYP2C8, CYP2D6, CYP3A4, P-gp
In vitro data suggest that chloroquine is metabolized primarily by CYP2C8 and CYP3A4, and to a much lesser
extent, by CYP2D6.[65236] [65239] It has also been shown to be an inhibitor of the drug transporter P-
glycoprotein (P-gp).[65237]
Route-Specific Pharmacokinetics
Oral Route
After oral administration, chloroquine is rapidly and almost completely absorbed from the
gastrointestinal tract.[29758][62151] The Tmax is 2.7 to 6.9 hours with a Cmax of 283 to 1,430 ng/mL
and an AUC of 8.2 to 140 mcg x hour/mL.[62151] A single study showed that the AUC in patients
with malaria was higher than in normal volunteers (281 vs. 122 mcg x mL/L x hour).[61760]
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Pregnancy/Breast-feeding
Pregnancy
Weigh the benefit of chloroquine prophylaxis or treatment of malaria against the potential risk to the fetus, and
consider the drug's potential to remain in the body for several months after discontinuation of therapy.[29758] 
[63990] [64059] In humans at recommended doses for prophylaxis and treatment of malaria, observational studies
as well as a meta-analysis, including a small number of prospective studies with chloroquine during pregnancy,
have shown no increase in the rate of birth defects or spontaneous abortions.[29758] Guidelines recommend
chloroquine as a treatment option for acute malaria and for prophylaxis in pregnant women during all trimesters.
Chloroquine crosses the placenta, but the potential damage to the mother from malaria is greater than the drug's
risk to the fetus. Weekly prophylactic doses appear to have minimal adverse effects when administered during
pregnancy.[63990] [64059] Animal studies showed embryo-fetal developmental toxicity at doses 3 to 16 times the
maximum recommended therapeutic dose and the potential of genotoxicity in some test systems.
Autoradiographic studies have shown accumulation in the eyes and ears when chloroquine is administered at the
start or end of gestation in animal studies.[29758]
Breast-Feeding
Use caution when administering chloroquine to breast-feeding women. Chloroquine is excreted into breast milk.
The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in
11 lactating mothers following a single oral dose of chloroquine (600 mg base).The maximum daily dose of the
drug that the infant received from breast-feeding was about 0.7% of the maternal start dose of the drug in
malaria chemotherapy. Separate chemoprophylaxis for an infant is required.[29758] However, previous American
Academy of Pediatrics (AAP) recommendations consider chloroquine usually compatible with breast-feeding,
and chloroquine has an established dosage in infants.[27500]
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Interactions
Level 1 (Severe)
Level 2 (Major)
Cisapride
Dronedarone
Pimozide
Thioridazine
Acarbose
Acetohexamide
Aclidinium; Formoterol
Albiglutide
Albuterol
Albuterol; Ipratropium
Alfuzosin
Alogliptin
Alogliptin; Metformin
Alogliptin; Pioglitazone
Alpha-glucosidase Inhibitors
Aluminum Hydroxide
Aluminum Hydroxide; Magnesium Carbonate
Aluminum Hydroxide; Magnesium Hydroxide
Aluminum Hydroxide; Magnesium Hydroxide;
Simethicone
Aluminum Hydroxide; Magnesium Trisilicate
Amiodarone
Amitriptyline
Amitriptyline; Chlordiazepoxide
Amoxicillin; Clarithromycin; Lansoprazole
Amoxicillin; Clarithromycin; Omeprazole
Anagrelide
Antacids
Apomorphine
Arformoterol
Aripiprazole
Arsenic Trioxide
Artemether; Lumefantrine
Asenapine
Aspirin, ASA; Citric Acid; Sodium
Bicarbonate
Atomoxetine
Azithromycin
Bedaquiline
Bismuth Subcitrate Potassium; Metronidazole;
Tetracycline
Bismuth Subsalicylate; Metronidazole;
Tetracycline
Budesonide; Formoterol
Buprenorphine
Buprenorphine; Naloxone
Calcium Carbonate
Calcium Carbonate; Magnesium Hydroxide
Calcium Carbonate; Risedronate
Calcium Carbonate; Simethicone
Canagliflozin
Canagliflozin; Metformin
Ceritinib
Chlorpromazine
Chlorpropamide
Cimetidine
Ciprofloxacin
Citalopram
Clarithromycin
Clofazimine
Clomipramine
Clozapine
Codeine; Phenylephrine; Promethazine
Codeine; Promethazine
Crizotinib
Cyclosporine
Dapagliflozin
Dapagliflozin; Metformin
Dapagliflozin; Saxagliptin
Dasatinib
Degarelix
Desflurane
Desipramine
Deutetrabenazine
Dextromethorphan; Promethazine
Dextromethorphan; Quinidine
Dipeptidyl Peptidase-4 Inhibitors
Disopyramide
Dofetilide
Dolasetron
Dolutegravir; Rilpivirine
Donepezil
Donepezil; Memantine
Doxepin
Droperidol
Dulaglutide
Efavirenz
Efavirenz; Emtricitabine; Tenofovir
Efavirenz; Lamivudine; Tenofovir Disoproxil
Fumarate
Eliglustat
Empagliflozin
Empagliflozin; Linagliptin
Empagliflozin; Linagliptin; Metformin
Empagliflozin; Metformin
Emtricitabine; Rilpivirine; Tenofovir
alafenamide
Emtricitabine; Rilpivirine; Tenofovir disoproxil
fumarate
Encorafenib
Enflurane
Entrectinib
Eribulin
Ertugliflozin
Ertugliflozin; Metformin
Ertugliflozin; Sitagliptin
Erythromycin
Erythromycin; Sulfisoxazole
Escitalopram
Exenatide
Ezogabine
Fingolimod
Flecainide
Fluconazole
Fluoxetine
Fluoxetine; Olanzapine
Fluphenazine
Fluticasone; Salmeterol
Fluticasone; Umeclidinium; Vilanterol
Fluticasone; Vilanterol
Fluvoxamine
Formoterol
Formoterol; Mometasone
Foscarnet
Gemifloxacin
Gemtuzumab Ozogamicin
Gilteritinib
Glasdegib
Glimepiride
Glimepiride; Pioglitazone
Glimepiride; Rosiglitazone
Glipizide
Glipizide; Metformin
Glyburide
Glyburide; Metformin
Glycopyrrolate; Formoterol
Goserelin
Granisetron
Halogenated Anesthetics
Haloperidol
Halothane
Histrelin
Hydroxyzine
Ibutilide
Iloperidone
Imipramine
Incretin Mimetics
Indacaterol
Indacaterol; Glycopyrrolate
Inotuzumab Ozogamicin
Insulin Aspart
Insulin Aspart; Insulin Aspart Protamine
Insulin Degludec
Insulin Degludec; Liraglutide
Insulin Detemir
Insulin Glargine
Insulin Glargine; Lixisenatide
Insulin Glulisine
Insulin Lispro
Insulin Lispro; Insulin Lispro Protamine
Insulin, Inhaled
Insulins
Isoflurane
Isophane Insulin (NPH)
Itraconazole
Ivosidenib
Ketoconazole
Lanthanum Carbonate
Lapatinib
Lefamulin
Lente Insulin
Lenvatinib
Leuprolide
Leuprolide; Norethindrone
Levalbuterol
Levofloxacin
Linagliptin
Linagliptin; Metformin
Liraglutide
Lithium
Lixisenatide
Lofexidine
Lomefloxacin
Long-acting beta-agonists
Loperamide
Loperamide; Simethicone
Lopinavir; Ritonavir
Macimorelin
Magnesium Hydroxide
Maprotiline
Mefloquine
Meglitinides
Meperidine; Promethazine
Metaproterenol
Metformin
Metformin; Pioglitazone
Metformin; Repaglinide
Metformin; Rosiglitazone
Metformin; Saxagliptin
Metformin; Sitagliptin
Methadone
Metronidazole
Midostaurin
Mifepristone
Miglitol
Mirtazapine
Moxifloxacin
Nateglinide
Nilotinib
Norfloxacin
Nortriptyline
Octreotide
Ofloxacin
Olanzapine
Olodaterol
Omeprazole; Sodium Bicarbonate
Ondansetron
Osilodrostat
Osimertinib
Oxaliplatin
Level 3 (Moderate)
Paliperidone
Panobinostat
Pasireotide
Pazopanib
Penicillamine
Pentamidine
Perphenazine
Perphenazine; Amitriptyline
Phenylephrine; Promethazine
Pimavanserin
Pioglitazone
Pirbuterol
Pitolisant
Posaconazole
Pramlintide
Primaquine
Procainamide
Prochlorperazine
Promethazine
Propafenone
Protriptyline
Quetiapine
Quinidine
Quinine
Rabies Vaccine
Ranolazine
Regular Insulin
Regular Insulin; Isophane Insulin (NPH)
Repaglinide
Ribociclib
Ribociclib; Letrozole
Rilpivirine
Risperidone
Romidepsin
Rosiglitazone
Salmeterol
Saquinavir
Saxagliptin
Semaglutide
Sertraline
Sevoflurane
SGLT2 Inhibitors
Short-acting beta-agonists
Simvastatin; Sitagliptin
Siponimod
Sitagliptin
Sodium Bicarbonate
Solifenacin
Sorafenib
Sotalol
Sulfonylureas
Sunitinib
Tacrolimus
Tamoxifen
Telavancin
Telithromycin
Terbutaline
Tetrabenazine
Thiazolidinediones
Tiotropium; Olodaterol
Tolazamide
Tolbutamide
Tolterodine
Toremifene
Trazodone
Tricyclic antidepressants
Trifluoperazine
Trimipramine
Triptorelin
Ultralente Insulin
Umeclidinium; Vilanterol
Vandetanib
Vardenafil
Vemurafenib
Venlafaxine
Vigabatrin
Voriconazole
Vorinostat
Ziprasidone
Ampicillin
Articaine; Epinephrine
Atropine; Hyoscyamine; Phenobarbital;
Scopolamine
Belladonna Alkaloids; Ergotamine;
Phenobarbital
Betrixaban
Bupivacaine
Bupivacaine Liposomal
Bupivacaine; Lidocaine
Carbamazepine
Chloroprocaine
Cobimetinib
Dabigatran
Dapsone
Digoxin
Edoxaban
Interferon Alfa-2a
Interferon Alfa-2b
Interferon Alfa-2b; Ribavirin
Level 4 (Minor)
Acarbose: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the alpha-glucosidase inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Acetohexamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent
may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine
and an antidiabetic agent. [29758]
Aclidinium; Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Albiglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Albuterol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28229] 
[28532] [29758] [49951] [51793] [59321] [65157] [65170]
Interferon Alfa-n3
Interferon Alfacon-1
Interferon Beta-1a
Interferon Beta-1b
Interferon Gamma-1b
Interferons
Lidocaine
Mepivacaine
Mepivacaine; Levonordefrin
Peginterferon Alfa-2a
Peginterferon Alfa-2b
Peginterferon beta-1a
Penicillin G Benzathine; Penicillin G Procaine
Penicillin G Procaine
Phenobarbital
Phenytoin
Ponatinib
Prilocaine
Prilocaine; Epinephrine
Ropivacaine
Succinylcholine
Tetracaine
Trametinib
Praziquantel Telbivudine
Albuterol; Ipratropium: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-
agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Alfuzosin: (Major) Avoid coadministration of chloroquine with alfuzosin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Alfuzosin may prolong the QT interval
in a dose-dependent manner. [28229] [28230] [28231] [28261] [65157] [65170]
Alogliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Alogliptin; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758]
Alogliptin; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is
recommended when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Alpha-glucosidase Inhibitors: (Major) Careful monitoring of blood glucose is recommended when chloroquine
and antidiabetic agents, including the alpha-glucosidase inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758]
Aluminum Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine
and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Carbonate: (Major) Chloroquine absorption may be reduced by antacids.
Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids.
Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: (Major) Chloroquine absorption may be reduced
by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Trisilicate: (Major) Chloroquine absorption may be reduced by antacids.
Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Amiodarone: (Major) Avoid coadministration of chloroquine with amiodarone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Amiodarone, a Class III antiarrhythmic
agent, is associated with a well-established risk of QT prolongation and torsade de pointes (TdP). Although the
frequency of TdP is less with amiodarone than with other Class III agents, amiodarone is still associated with a
risk of TdP. Due to the extremely long half-life of amiodarone, a drug interaction is possible for days to weeks
after discontinuation of amiodarone. [28224] [28229] [28230] [28231] [28432] [28457] [65157] [65170]
Amitriptyline: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Amitriptyline; Chlordiazepoxide: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the
QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). 
[28225] [28229] [28230] [28231] [28415] [28416] [29758] [65157] [65170]
Amoxicillin; Clarithromycin; Lansoprazole: (Major) Avoid coadministration of chloroquine with clarithromycin
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Clarithromycin is associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] 
[28238] [29758] [59321] [65157] [65170]
Amoxicillin; Clarithromycin; Omeprazole: (Major) Avoid coadministration of chloroquine with clarithromycin
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Clarithromycin is associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] 
[28238] [29758] [59321] [65157] [65170]
Ampicillin: (Moderate) Administer oral ampicillin 2 hours before or 2 hours after chloroquine. In a study of
healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. The reduction of
ampicillin bioavailability could be attributed to slower gastric emptying and enhancement of gut motility
produced by chloroquine. [29758] [61761]
Anagrelide: (Major) Avoid coadministration of chloroquine with anagrelide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. TdP and ventricular tachycardia have
been reported with anagrelide. In addition, dose-related increases in mean QTc and heart rate were observed in
healthy subjects. [28229] [28230] [28231] [29758] [30163] [65157] [65170]
Antacids: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids at
least 4 hours apart. [29758] [30285]
Apomorphine: (Major) Avoid coadministration of chloroquine with apomorphine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes; the risk
of QT prolongation is increased with higher chloroquine doses. Dose-related QTc prolongation is associated
with therapeutic apomorphine exposure. [28229] [28661] [29758] [59321] [65157] [65170]
Arformoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Aripiprazole: (Major) Avoid coadministration of chloroquine with aripiprazole due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has occurred during
therapeutic use of aripiprazole and following overdose. [28229] [28230] [28231] [29758] [42845] [53394] [60196] 
[65157] [65170]
Arsenic Trioxide: (Major) Avoid coadministration of chloroquine with arsenic trioxide due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TdP, QT interval
prolongation, and complete atrioventricular block have been reported with arsenic trioxide use. [28226] [28229] 
[28230] [28231] [65157] [65170]
Artemether; Lumefantrine: (Major) Avoid coadministration of chloroquine with artemether; lumefantrine due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Artemether;
lumefantrine is associated with prolongation of the QT interval. [28229] [28230] [28231] [29758] [35401] [65157] 
[65170]
Articaine; Epinephrine: (Moderate) Coadministration of articaine with oxidizing agents, such as chloroquine,
may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
articaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [28996]
Asenapine: (Major) Avoid coadministration of chloroquine with asenapine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Asenapine has also been associated with
QT prolongation. [28229] [28230] [28231] [29758] [36343] [65157] [65170]
Aspirin, ASA; Citric Acid; Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids.
Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Atomoxetine: (Major) Avoid coadministration of chloroquine with atomoxetine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has occurred during
therapeutic use of atomoxetine and following overdose. [28229] [28230] [28231] [28405] [29758] [59321] [65157] 
[65170]
Atropine; Hyoscyamine; Phenobarbital; Scopolamine: (Moderate) Coadministration of chloroquine and
phenobarbital may decrease exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in
vitro CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. [65210] [65237] [65239]
Azithromycin: (Major) Avoid coadministration of chloroquine with azithromycin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances (See Therapeutic Drug Monitoring for recommendations specific to COVID-19). Chloroquine is
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation
is increased with higher chloroquine doses. QT prolongation and torsade de pointes (TdP) have been
spontaneously reported during azithromycin postmarketing surveillance. [28229] [28230] [28231] [28855] [29758] 
[43974] [65157] [65170]
Bedaquiline: (Major) Avoid coadministration of chloroquine with bedaquiline due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Discontinue bedaquiline if evidence of serious ventricular arrhythmia or QTcF interval greater than
500 msec. Bedaquiline prolongs the QT interval. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. [28229] [28230] [28231] [29758] [52746] [65157] [65170]
Belladonna Alkaloids; Ergotamine; Phenobarbital: (Moderate) Coadministration of chloroquine and
phenobarbital may decrease exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in
vitro CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. [65210] [65237] [65239]
Betrixaban: (Moderate) Use caution if chloroquine is coadministered with betrixaban due to the potential for
increased betrixaban exposure which may increase the risk of bleeding. Betrixaban is a P-gp substrate; limited
data suggests that chloroquine is a P-gp inhibitor. [62037] [65210]
Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: (Major) Avoid coadministration of chloroquine
with metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher
chloroquine doses. Potential QT prolongation has been reported in limited case reports with metronidazole. 
[28229] [28230] [28231] [29758] [57377] [57378] [65157] [65170]
Bismuth Subsalicylate; Metronidazole; Tetracycline: (Major) Avoid coadministration of chloroquine with
metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher
chloroquine doses. Potential QT prolongation has been reported in limited case reports with metronidazole. 
[28229] [28230] [28231] [29758] [57377] [57378] [65157] [65170]
Budesonide; Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Bupivacaine Liposomal: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is
suspected, discontinue bupivacaine and any other oxidizing agents. Depending on the severity of symptoms,
patients may respond to supportive care; more severe symptoms may require treatment with methylene blue,
exchange transfusion, or hyperbaric oxygen. [52331]
Bupivacaine: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as chloroquine, may
increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
bupivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [52331]
Bupivacaine; Lidocaine: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is
suspected, discontinue bupivacaine and any other oxidizing agents. Depending on the severity of symptoms,
patients may respond to supportive care; more severe symptoms may require treatment with methylene blue,
exchange transfusion, or hyperbaric oxygen. [52331] (Moderate) Coadministration of lidocaine with oxidizing
agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely
for signs and symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs
or is suspected, discontinue lidocaine and any other oxidizing agents. Depending on the severity of symptoms,
patients may respond to supportive care; more severe symptoms may require treatment with methylene blue,
exchange transfusion, or hyperbaric oxygen. [43383]
Buprenorphine: (Major) Avoid coadministration of chloroquine with buprenorphine due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Buprenorphine has been
associated with QT prolongation and has a possible risk of TdP. [28229] [28230] [28231] [29758] [41235] [59321] 
[60270] [65157] [65170]
Buprenorphine; Naloxone: (Major) Avoid coadministration of chloroquine with buprenorphine due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Buprenorphine
has been associated with QT prolongation and has a possible risk of TdP. [28229] [28230] [28231] [29758] [41235] 
[59321] [60270] [65157] [65170]
Calcium Carbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and
antacids at least 4 hours apart. [29758] [30284] [30285]
Calcium Carbonate; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids.
Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285] (Major) Chloroquine
absorption may be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] 
[30285]
Calcium Carbonate; Risedronate: (Major) Chloroquine absorption may be reduced by antacids. Administer
chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Calcium Carbonate; Simethicone: (Major) Chloroquine absorption may be reduced by antacids. Administer
chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Canagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Canagliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Carbamazepine: (Moderate) Coadministration of chloroquine and carbamazepine may decrease exposure of
chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and
carbamazepine is a strong CYP3A4 inducer. [65210] [65237] [65239]
Ceritinib: (Major) Avoid coadministration of chloroquine with ceritinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Interrupt, dose reduce, or discontinue ceritinib if QT prolongation occurs. Ceritinib causes
concentration-dependent QT prolongation. Chloroquine is associated with an increased risk of QT prolongation
and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] 
[28230] [28231] [29758] [34353] [57094] [65157] [65170]
Chloroprocaine: (Moderate) Coadministration of chloroprocaine with oxidizing agents, such as chloroquine,
may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
chloroprocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [29062]
Chlorpromazine: (Major) Avoid coadministration of chloroquine with chlorpromazine due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Chlorpromazine is
associated with an established risk of QT prolongation and TdP. [28229] [28230] [28231] [29758] [43065] [59321] 
[65157] [65170]
Chlorpropamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent
may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine
and an antidiabetic agent. [29758]
Cimetidine: (Major) Avoid concomitant use of chloroquine and cimetidine as cimetidine may inhibit the
metabolism of chloroquine, increasing its plasma concentration. [29758] [34335] [34353] [61759] [61760]
Ciprofloxacin: (Major) Avoid coadministration of chloroquine with ciprofloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Rare cases of QT prolongation and TdP
have been reported with ciprofloxacin during postmarketing surveillance. [28229] [28230] [28231] [29758] [43411] 
[46655] [65157] [65170]
Cisapride: (Severe) Coadministration of chloroquine with cisapride is contraindicated due to the increased risk
of QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes
(TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and ventricular
arrhythmias, including TdP and death, have been reported with cisapride. [28229] [28230] [28231] [29758] [47221] 
[65157] [65170]
Citalopram: (Major) Avoid coadministration of chloroquine with citalopram due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Citalopram causes dose-dependent QT
interval prolongation. [28229] [28230] [28231] [28269] [29758] [65157] [65170]
Clarithromycin: (Major) Avoid coadministration of chloroquine with clarithromycin due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is
associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238] [29758] [59321] 
[65157] [65170]
Clofazimine: (Major) Avoid coadministration of chloroquine with clofazimine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP have been
reported in patients receiving clofazimine in combination with QT prolonging medications. [28229] [28230] 
[28231] [29758] [63936] [65157] [65170]
Clomipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Clozapine: (Major) Avoid coadministration of chloroquine with clozapine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Treatment with clozapine has been
associated with QT prolongation, TdP, cardiac arrest, and sudden death. [28229] [28230] [28231] [28262] [29758] 
[65157] [65170]
Cobimetinib: (Moderate) Concurrent use of chloroquine and cobimetinib is not recommended as there is an
increased risk of retinal toxicity. [29758] [60281]
Codeine; Phenylephrine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging
drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation
and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses.
Promethazine is associated with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] 
[55578] [65157] [65170]
Codeine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Promethazine is
associated with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170]
Crizotinib: (Major) Avoid coadministration of chloroquine with crizotinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for
crizotinib if QT prolongation occurs. Crizotinib can cause concentration-dependent QT prolongation.
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT
prolongation is increased with higher chloroquine doses. [28229] [28231] [29758] [45458] [65157] [65170]
Cyclosporine: (Major) Close monitoring of serum cyclosporine concentrations is recommended during
coadministration of chloroquine. Sudden increases in cyclosporine concentrations have been reported after the
addition of chloroquine. Discontinue chloroquine if necessary. [29758]
Dabigatran: (Moderate) Use caution if chloroquine is coadministered with dabigatran due to the potential for
increased dabigatran exposure which may increase the risk of bleeding. Dabigatran is a P-gp substrate; limited
data suggests that chloroquine is a P-gp inhibitor. [42121] [65210]
Dapagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Dapagliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Dapagliflozin; Saxagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is
recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Dapsone: (Moderate) Coadministration of dapsone with chloroquine may increase the risk of developing
methemoglobinemia. Advise patients to discontinue treatment and seek immediate medical attention with any
signs or symptoms of methemoglobinemia. [60612]
Dasatinib: (Major) Avoid coadministration of chloroquine with dasatinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. In vitro studies have shown that
dasatinib has the potential to prolong the QT interval. [28229] [28230] [28231] [29758] [32387] [65157] [65170]
Degarelix: (Major) Avoid coadministration of chloroquine with degarelix due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e.,
degarelix) may also prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [46869] [65157] [65170]
Desflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics
are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] 
[59321] [65157] [65170]
Desipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Deutetrabenazine: (Major) Avoid coadministration of chloroquine with deutetrabenazine due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. For patients taking a deutetrabenazine dosage more than 24 mg/day, assess the QTc
interval before and after increasing the deutetrabenazine dosage or other medications that prolong the QTc
interval. Clinically relevant QTc prolongation may occur with deutetrabenazine. Chloroquine is associated with
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with
higher chloroquine doses. [28229] [28230] [28231] [29758] [61845] [65157] [65170]
Dextromethorphan; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Promethazine
is associated with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] 
[65170]
Dextromethorphan; Quinidine: (Major) Avoid coadministration of chloroquine with quinidine due to the
increased risk of QT prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline
to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential
QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Quinidine administration is also associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] 
[42280] [47357] [65157] [65170]
Digoxin: (Moderate) Monitor serum digoxin concentrations in patients receiving digoxin and chloroquine as
coadministration may result in increased serum digoxin concentrations. Digoxin serum concentrations have been
reported to increase when hydroxychloroquine was added. Although this interaction has not been reported with
chloroquine, chloroquine may similarly increase the plasma concentration of digoxin. [41806] [60957]
Dipeptidyl Peptidase-4 Inhibitors: (Major) Careful monitoring of blood glucose is recommended when
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Disopyramide: (Major) Avoid coadministration of chloroquine with disopyramide due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Disopyramide
administration is associated with QT prolongation and TdP. [28228] [28229] [28230] [28231] [29758] [65157] [65170]
Dofetilide: (Major) Avoid coadministration of chloroquine with dofetilide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Dofetilide, a Class III antiarrhythmic
agent, is associated with a well-established risk of QT prolongation and TdP. [28221] [28229] [28230] [28231] 
[28432] [28457] [29758] [65157] [65170]
Dolasetron: (Major) Avoid coadministration of chloroquine with dolasetron due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Dolasetron has been associated with a
dose-dependent prolongation of the QT, PR, and QRS intervals on an electrocardiogram. [28229] [28230] [28231] 
[29758] [34353] [42844] [55935] [65157] [65170]
Dolutegravir; Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of
rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] 
[65170]
Donepezil: (Major) Avoid coadministration of chloroquine with donepezil due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Case reports indicate that QT
prolongation and TdP can occur during donepezil therapy. [28229] [28230] [28231] [29758] [59321] [59322] [65157] 
[65170]
Donepezil; Memantine: (Major) Avoid coadministration of chloroquine with donepezil due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Case reports indicate that
QT prolongation and TdP can occur during donepezil therapy. [28229] [28230] [28231] [29758] [59321] [59322] 
[65157] [65170]
Doxepin: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Dronedarone: (Severe) Coadministration of chloroquine with dronedarone is contraindicated due to the
increased risk of QT prolongation. Dronedarone administration is associated with a dose-related increase in the
QTc interval. The increase in QTc is approximately 10 milliseconds at doses of 400 mg twice daily (the FDA-
approved dose) and up to 25 milliseconds at doses of 1,600 mg twice daily. Chloroquine is associated with an
increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with
higher chloroquine doses. [28229] [28230] [28231] [29758] [36101] [65157] [65170]
Droperidol: (Major) Avoid coadministration of chloroquine with droperidol due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Initiate droperidol at a low dose and increase the dose as needed to achieve the desired effect.
Droperidol administration is associated with an established risk for QT prolongation and torsade de pointes
(TdP). Some cases have occurred in patients with no known risk factors for QT prolongation and some cases
have been fatal. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes
(TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28231] [28235] [28236] 
[28237] [28737] [29758] [51289] [59321] [65157] [65170]
Dulaglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Edoxaban: (Moderate) Use caution if chloroquine is coadministered with edoxaban due to the potential for
increased edoxaban exposure which may increase the risk of bleeding. Edoxaban is a P-gp substrate; limited data
suggests that chloroquine is a P-gp inhibitor. [58685] [65210]
Efavirenz: (Major) Avoid coadministration of chloroquine with efavirenz due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QTc prolongation has been observed
with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] [65157] [65170]
Efavirenz; Emtricitabine; Tenofovir: (Major) Avoid coadministration of chloroquine with efavirenz due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QTc
prolongation has been observed with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] [65157] [65170]
Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of chloroquine with
efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. QTc prolongation has been observed with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] 
[65157] [65170]
Eliglustat: (Major) Avoid coadministration of chloroquine with eliglustat due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Eliglustat is predicted to cause PR, QRS,
and/or QT prolongation at significantly elevated plasma concentrations. [28229] [28230] [28231] [29758] [57803] 
[65157] [65170]
Empagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Empagliflozin; Linagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is
recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Empagliflozin; Linagliptin; Metformin: (Major) Careful monitoring of blood glucose is recommended when
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is
recommended when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including the SGLT2
inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent. 
[29758]
Empagliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Major) Avoid coadministration of chloroquine with
rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] 
[28231] [29758] [44376] [65157] [65170]
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: (Major) Avoid coadministration of chloroquine with
rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] 
[28231] [29758] [44376] [65157] [65170]
Encorafenib: (Major) Avoid coadministration of chloroquine with encorafenib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Encorafenib has been associated with
dose-dependent QT prolongation. [28229] [28230] [28231] [29758] [63317] [65157] [65170]
Enflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics
are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] 
[59321] [65157] [65170]
Entrectinib: (Major) Avoid coadministration of chloroquine with entrectinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Entrectinib has been associated with QT
prolongation. [28229] [28230] [28231] [29758] [64567] [65157] [65170]
Eribulin: (Major) Avoid coadministration of chloroquine with eribulin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Eribulin has been associated with QT
prolongation. [28229] [28230] [28231] [29758] [42449] [65157] [65170]
Ertugliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Ertugliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Ertugliflozin; Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is
recommended when chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Erythromycin: (Major) Avoid coadministration of chloroquine with erythromycin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Erythromycin is associated with QT
prolongation and TdP. [28229] [28230] [28231] [29758] [43258] [59321] [65157] [65170]
Erythromycin; Sulfisoxazole: (Major) Avoid coadministration of chloroquine with erythromycin due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Erythromycin
is associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] [43258] [59321] [65157] [65170]
Escitalopram: (Major) Avoid coadministration of chloroquine with escitalopram due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Escitalopram has been associated with a
risk of QT prolongation and TdP. [28229] [28230] [28231] [28270] [29758] [65157] [65170]
Exenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Ezogabine: (Major) Avoid coadministration of chloroquine with ezogabine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Ezogabine has been associated with QT
prolongation. [28229] [28230] [28231] [29758] [44800] [65157] [65170]
Fingolimod: (Major) Avoid coadministration of chloroquine with fingolimod due to the increased risk of QT
prolongation. If use together is necessary, overnight monitoring with continuous ECG in a medical facility is
advised after the first dose of fingolimod; monitor ECG closely throughout therapy, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Fingolimod initiation results in decreased heart rate and may prolong the QT interval. Fingolimod has not
been studied in patients treated with drugs that prolong the QT interval, but drugs that prolong the QT interval
have been associated with cases of TdP in patients with bradycardia. [28229] [28230] [28231] [29758] [65157] 
[65170]
Flecainide: (Major) Avoid coadministration of chloroquine with flecainide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Flecainide is a Class IC antiarrhythmic
associated with a possible risk for QT prolongation and/or TdP; flecainide increases the QT interval, but largely
due to prolongation of the QRS interval. Although causality for TdP has not been established for flecainide,
patients receiving concurrent drugs that have the potential for QT prolongation may have an increased risk of
developing proarrhythmias. [23774] [28229] [28230] [28231] [28752] [29758] [51070] [65157] [65170]
Fluconazole: (Major) Avoid coadministration of chloroquine with fluconazole due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Fluconazole has been associated with
QT prolongation and rare cases of TdP. [28229] [28230] [28231] [28674] [29758] [60686] [65157] [65170]
Fluoxetine: (Major) Avoid coadministration of chloroquine with fluoxetine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP have been
reported in patients treated with fluoxetine. [28229] [28230] [28231] [29758] [32127] [44058] [44059] [65157] [65170]
Fluoxetine; Olanzapine: (Major) Avoid coadministration of chloroquine with fluoxetine due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP
have been reported in patients treated with fluoxetine. [28229] [28230] [28231] [29758] [32127] [44058] [44059] 
[65157] [65170] (Major) Avoid coadministration of chloroquine with olanzapine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Limited data, including some case
reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28229] 
[28230] [28231] [28785] [29758] [32732] [32734] [32745] [65157] [65170]
Fluphenazine: (Major) Avoid coadministration of chloroquine with fluphenazine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Fluphenazine is associated with a
possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [59321] [65157] [65170]
Fluticasone; Salmeterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Fluticasone; Umeclidinium; Vilanterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation,
usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the
QT interval. This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Fluticasone; Vilanterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Fluvoxamine: (Major) Avoid coadministration of chloroquine with fluvoxamine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP has been
reported during fluvoxamine postmarketing use. [28229] [28230] [28231] [29758] [50507] [65157] [65170]
Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting beta-agonists.. 
[28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Formoterol; Mometasone: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Foscarnet: (Major) Avoid coadministration of chloroquine with foscarnet due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Both QT prolongation and TdP have
been reported during postmarketing use of foscarnet. [28229] [28230] [28231] [28377] [29758] [65157] [65170]
Gemifloxacin: (Major) Avoid coadministration of chloroquine with gemifloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Gemifloxacin may prolong the QT
interval in some patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following
oral administration of gemifloxacin. The likelihood of QTc prolongation may increase with increasing
gemifloxacin dose; therefore, do not exceed the recommended dose, especially in patients with renal or hepatic
impairment where the Cmax and AUC are slightly higher. [28229] [28230] [28231] [28419] [28420] [28424] [29758] 
[65157] [65170]
Gemtuzumab Ozogamicin: (Major) Avoid coadministration of chloroquine with gemtuzumab due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Although QT
interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain
calicheamicin. [28229] [28230] [28231] [29758] [62292] [65157] [65170]
Gilteritinib: (Major) Avoid coadministration of chloroquine with gilteritinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Gilteritinib has been associated with QT
prolongation. [28229] [28230] [28231] [29758] [63787] [65157] [65170]
Glasdegib: (Major) Avoid coadministration of chloroquine with glasdegib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Glasdegib therapy may result in QT
prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia. [28229] 
[28230] [28231] [29758] [63777] [65157] [65170]
Glimepiride: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Glimepiride; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent
may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine
and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when
chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated
concomitantly with chloroquine and an antidiabetic agent. [29758]
Glimepiride; Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine
and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended
when chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased
dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated
concomitantly with chloroquine and an antidiabetic agent. [29758]
Glipizide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Glipizide; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent
may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine
and an antidiabetic agent. [29758]
Glyburide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Glyburide; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent
may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine
and an antidiabetic agent. [29758]
Glycopyrrolate; Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging
drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation
and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-
agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at
higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT
interval. This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to
short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Goserelin: (Major) Avoid coadministration of chloroquine with goserelin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e.,
goserelin) may also prolong the QT/QTc interval. [28229] [28230] [28231] [28592] [29758] [65157] [65170]
Granisetron: (Major) Avoid coadministration of chloroquine with granisetron due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Granisetron has been associated with QT
prolongation. [28229] [28230] [28231] [29758] [31723] [65157] [65170]
Halogenated Anesthetics: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated
anesthetics are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] 
[29758] [59321] [65157] [65170]
Haloperidol: (Major) Avoid coadministration of chloroquine with haloperidol due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and TdP have been
observed during haloperidol treatment. Excessive doses (particularly in the overdose setting) or IV
administration of haloperidol may be associated with a higher risk of QT prolongation. [23500] [23779] [28229] 
[28230] [28231] [28307] [28415] [29758] [59321] [65157] [65170]
Halothane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics
are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] 
[59321] [65157] [65170]
Histrelin: (Major) Avoid coadministration of chloroquine with histrelin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e.,
histrelin) may prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [30369] [65157] [65170]
Hydroxyzine: (Major) Avoid coadministration of chloroquine with hydroxyzine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Postmarketing data indicate that
hydroxyzine causes QT prolongation and TdP. [28229] [28230] [28231] [29758] [47129] [61470] [65157] [65170]
Ibutilide: (Major) Avoid coadministration of chloroquine with ibutilide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Ibutilide administration can cause QT
prolongation and TdP; proarrhythmic events should be anticipated. The potential for proarrhythmic events with
ibutilide increases with the use of other drugs that prolong the QT interval. [28229] [28230] [28231] [29758] [41830]
[65157] [65170]
Iloperidone: (Major) Avoid coadministration of chloroquine with iloperidone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Iloperidone has also been associated
with QT prolongation. [28229] [28230] [28231] [29758] [36146] [65157] [65170]
Imipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Incretin Mimetics: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Indacaterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting beta-agonists.. 
[28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Indacaterol; Glycopyrrolate: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging
drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation
and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-
agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at
higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT
interval. This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to
short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Inotuzumab Ozogamicin: (Major) Avoid coadministration of chloroquine with inotuzumab due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Inotuzumab has also been
associated with QT interval prolongation. [28229] [28230] [28231] [29758] [62245] [65157] [65170]
Insulin Aspart: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as
severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic
agent. [29758]
Insulin Aspart; Insulin Aspart Protamine: (Major) Careful monitoring of blood glucose is recommended when
chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Insulin Degludec: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Insulin Degludec; Liraglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Insulin Detemir: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Insulin Glargine: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Insulin Glargine; Lixisenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Insulin Glulisine: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Insulin Lispro: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as
severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic
agent. [29758]
Insulin Lispro; Insulin Lispro Protamine: (Major) Careful monitoring of blood glucose is recommended when
chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Insulin, Inhaled: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Insulins: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as
severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic
agent. [29758]
Interferon Alfa-2a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an
increased risk of retinal toxicity. [29758] [47391]
Interferon Alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an
increased risk of retinal toxicity. [29758] [47391]
Interferon Alfa-2b; Ribavirin: (Moderate) Concurrent use of chloroquine and interferons is not recommended as
there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Alfacon-1: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is
an increased risk of retinal toxicity. [29758] [47391]
Interferon Alfa-n3: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an
increased risk of retinal toxicity. [29758] [47391]
Interferon Beta-1a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an
increased risk of retinal toxicity. [29758] [47391]
Interferon Beta-1b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an
increased risk of retinal toxicity. [29758] [47391]
Interferon Gamma-1b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is
an increased risk of retinal toxicity. [29758] [47391]
Interferons: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is an
increased risk of retinal toxicity. [29758] [47391]
Isoflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics
are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] 
[59321] [65157] [65170]
Isophane Insulin (NPH): (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Itraconazole: (Major) Avoid coadministration of chloroquine with itraconazole due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Itraconazole has also been associated
with prolongation of the QT interval. [27983] [28229] [28230] [28231] [29758] [40233] [57441] [63821] [65157] [65170]
Ivosidenib: (Major) Avoid coadministration of chloroquine with ivosidenib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation
occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with
ivosidenib. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [65157] 
[65170]
Ketoconazole: (Major) Avoid coadministration of chloroquine with systemic ketoconazole due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ketoconazole has been
associated with prolongation of the QT interval. [27982] [28229] [28230] [28231] [29758] [59321] [65157] [65170]
Lanthanum Carbonate: (Major) Oral compounds known to interact with antacids, like chloroquine, should not be
taken within 4 hours of dosing with lanthanum carbonate. If these agents are used concomitantly, space the
dosing intervals appropriately. Monitor serum concentrations and clinical condition. [29758] [30284] [30285] 
[44406]
Lapatinib: (Major) Avoid coadministration of chloroquine with lapatinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Lapatinib has been associated with
concentration-dependent QT prolongation; ventricular arrhythmias and TdP have been reported in postmarketing
experience with lapatinib. [28229] [28230] [28231] [29758] [33192] [65157] [65170]
Lefamulin: (Major) Avoid coadministration of chloroquine with lefamulin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Lefamulin has a concentration
dependent QTc prolongation effect. The potential to prolong the QT interval of the ECG between lefamulin and
other drugs that effect cardiac conduction is unknown. [28229] [28230] [28231] [29758] [64576] [65157] [65170]
Lente Insulin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as
severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic
agent. [29758]
Lenvatinib: (Major) Avoid coadministration of chloroquine with lenvatinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Prolongation of the QT interval has been
reported with lenvatinib therapy. [28229] [28230] [28231] [29758] [58782] [65157] [65170]
Leuprolide: (Major) Avoid coadministration of chloroquine with leuprolide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e.,
leuprolide) may prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [43800] [65157] [65170]
Leuprolide; Norethindrone: (Major) Avoid coadministration of chloroquine with leuprolide due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation
therapy (i.e., leuprolide) may prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [43800] [65157] [65170]
Levalbuterol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-
agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Levofloxacin: (Major) Avoid coadministration of chloroquine with levofloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Levofloxacin has been associated with
prolongation of the QT interval and infrequent cases of arrhythmia. Additionally, rare cases of TdP have been
spontaneously reported during postmarketing surveillance in patients receiving levofloxacin. [28229] [28230] 
[28231] [28421] [29758] [61195] [63729] [65157] [65170]
Lidocaine: (Moderate) Coadministration of lidocaine with oxidizing agents, such as chloroquine, may increase
the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
lidocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [43383]
Linagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Linagliptin; Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758]
Liraglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Lithium: (Major) Avoid coadministration of chloroquine with lithium due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Lithium has also been associated with
QT prolongation. [28229] [28230] [28231] [29758] [59809] [59810] [59811] [65157] [65170]
Lixisenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Lofexidine: (Major) Avoid coadministration of chloroquine with lofexidine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Lofexidine also prolongs the QT
interval. [28229] [28230] [28231] [29758] [63161] [65157] [65170]
Lomefloxacin: (Major) Avoid coadministration of chloroquine with lomefloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Cases of QT prolongation and TdP have
been reported with lomefloxacin. [29758] [29948] [59321]
Long-acting beta-agonists: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Loperamide: (Major) Avoid coadministration of chloroquine with loperamide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. At high doses, loperamide has been
associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation,TdP, and
cardiac arrest. [28229] [28230] [28231] [29758] [30106] [60864] [65157] [65170]
Loperamide; Simethicone: (Major) Avoid coadministration of chloroquine with loperamide due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. At high doses,
loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT
prolongation,TdP, and cardiac arrest. [28229] [28230] [28231] [29758] [30106] [60864] [65157] [65170]
Lopinavir; Ritonavir: (Major) Avoid coadministration of chloroquine and lopinavir due the risk of additive QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
fatalities have been reported. The risk of QT prolongation is increased with higher chloroquine doses. Lopinavir
is also associated with QT prolongation. [28229] [28230] [28231] [28341] [29758] [65157] [65170]
Macimorelin: (Major) Avoid coadministration of chloroquine with macimorelin due to the increased risk of QT
prolongation and torsade de pointes-type ventricular tachycardia. Allow a sufficient washout period before
starting macimorelin. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Treatment with
macimorelin has been associated with an increase in the corrected QT (QTc) interval. [28229] [28230] [28231] 
[29758] [62723] [65157] [65170]
Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine
and antacids at least 4 hours apart. [29758] [30285]
Maprotiline: (Major) Avoid coadministration of chloroquine with maprotiline due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Maprotiline has been reported to prolong
the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum
concentrations). Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but
rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk
factors for QT prolongation. Limited data are available regarding the safety of maprotiline in combination with
other QT-prolonging drugs. [28225] [28229] [28230] [28231] [29758] [51740] [65157] [65170]
Mefloquine: (Major) Avoid coadministration of chloroquine with mefloquine due to the increased risk of QT
prolongation and seizures. These drugs are both analogs of quinine. If use together is necessary, obtain an ECG
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher
chloroquine doses. There is evidence that the use of halofantrine after mefloquine causes a significant
lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. Also, both
drugs may lower the seizure threshold. [28229] [28230] [28231] [28301] [29758] [65157] [65170]
Meglitinides: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Meperidine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Promethazine
is associated with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] 
[65170]
Mepivacaine: (Moderate) Coadministration of mepivacaine with oxidizing agents, such as chloroquine, may
increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
mepivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [29100]
Mepivacaine; Levonordefrin: (Moderate) Coadministration of mepivacaine with oxidizing agents, such as
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is
suspected, discontinue mepivacaine and any other oxidizing agents. Depending on the severity of symptoms,
patients may respond to supportive care; more severe symptoms may require treatment with methylene blue,
exchange transfusion, or hyperbaric oxygen. [29100]
Metaproterenol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-
agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be necessary as
severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic
agent. [29758]
Metformin; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Metformin; Repaglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent
may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine
and an antidiabetic agent. [29758]
Metformin; Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Metformin; Saxagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758]
Metformin; Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758]
Methadone: (Major) Avoid coadministration of chloroquine with methadone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Methadone is considered to be
associated with an increased risk for QT prolongation and TdP, especially at higher doses (more than 200
mg/day but averaging approximately 400 mg/day in adult patients). Most cases involve patients being treated for
pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving
doses commonly used for maintenance treatment of opioid addiction. [28229] [28230] [28231] [28319] [28320] 
[28321] [28322] [29758] [33136] [65157] [65170]
Metronidazole: (Major) Avoid coadministration of chloroquine with metronidazole due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Potential QT
prolongation has been reported in limited case reports with metronidazole. [28229] [28230] [28231] [29758] [57377] 
[57378] [65157] [65170]
Midostaurin: (Major) Avoid coadministration of chloroquine with midostaurin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation was reported in patients
who received midostaurin in clinical trials. [28229] [28230] [28231] [29758] [61906] [65157] [65170]
Mifepristone: (Major) Avoid coadministration of chloroquine with mifepristone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Mifepristone is associated with dose-
related prolongation of the QT interval. [28229] [28230] [28231] [29758] [48697] [65157] [65170]
Miglitol: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the alpha-glucosidase inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Mirtazapine: (Major) Avoid coadministration of chloroquine with mirtazapine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Mirtazapine has been associated with
dose-dependent prolongation of the QT interval. TdP has been reported postmarketing, primarily in overdose or
in patients with other risk factors for QT prolongation. [28229] [28230] [28231] [29758] [40942] [65157] [65170]
Moxifloxacin: (Major) Avoid coadministration of chloroquine with moxifloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Quinolones have been associated with a
risk of QT prolongation.TdP has been reported during postmarketing surveillance of moxifloxacin. These reports
generally involved patients with concurrent medical conditions or concomitant medications that may have been
contributory. [28229] [28230] [28231] [28423] [29758] [59321] [65157] [65170]
Nateglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Nilotinib: (Major) Avoid coadministration of chloroquine with nilotinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Sudden death and QT interval
prolongation have occurred in patients who received nilotinib therapy. [28229] [28230] [28231] [29758] [58766] 
[65157] [65170]
Norfloxacin: (Major) Avoid coadministration of chloroquine with norfloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Quinolones have been associated with a
risk of QT prolongation and torsade de pointes (TdP). Although extremely rare,TdP has been reported during
postmarketing surveillance of norfloxacin. These reports generally involved patients with concurrent medical
conditions or concomitant medications that may have been contributory. [28225] [28229] [28230] [28231] [28432] 
[28457] [29758] [29818] [65157] [65170]
Nortriptyline: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Octreotide: (Major) Avoid coadministration of chloroquine with octreotide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Arrhythmias, sinus bradycardia, and
conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for
development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically
increase the risk of TdP in patients receiving drugs that prolong the QT interval. [28229] [28230] [28231] [28432] 
[29113] [29758] [30624] [64969] [65157] [65170]
Ofloxacin: (Major) Avoid coadministration of chloroquine with ofloxacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Quinolones have been associated with a
risk of QT prolongation and TdP. Although extremely rare, torsade de pointes has been reported during
postmarketing surveillance of ofloxacin. These reports generally involved patients with concurrent medical
conditions or concomitant medications that may have been contributory. [28229] [28230] [28231] [29758] [30738] 
[65157] [65170]
Olanzapine: (Major) Avoid coadministration of chloroquine with olanzapine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Limited data, including some case
reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28229] 
[28230] [28231] [28785] [29758] [32732] [32734] [32745] [65157] [65170]
Olodaterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting beta-agonists.. 
[28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Omeprazole; Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer
chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Ondansetron: (Major) Avoid coadministration of chloroquine with ondansetron due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Ondansetron has been associated with a
dose-related increase in the QT interval and postmarketing reports of TdP. [28229] [28230] [28231] [29758] [31266] 
[32722] [34335] [34353] [65157] [65170]
Osilodrostat: (Major) Avoid coadministration of chloroquine with osilodrostat due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Osilodrostat is associated with dose-
dependent QT prolongation. [28229] [28230] [28231] [29758] [65098] [65157] [65170]
Osimertinib: (Major) Avoid coadministration of chloroquine with osimertinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. An interruption of osimertinib therapy with dose reduction or discontinuation may be necessary if
QT prolongation occurs. Concentration-dependent QTc prolongation occurred during clinical trials of
osimertinib. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [60297] 
[65157] [65170]
Oxaliplatin: (Major) Avoid coadministration of chloroquine with oxaliplatin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation and ventricular
arrhythmias including fatal TdP have been reported with oxaliplatin use in postmarketing experience. [28229] 
[28230] [28231] [28415] [29758] [41958] [65157] [65170]
Paliperidone: (Major) Avoid coadministration of chloroquine with paliperidone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Paliperidone has been associated with
QT prolongation; TdP and ventricular fibrillation have been reported in the setting of overdose. [28229] [28230] 
[28231] [29758] [40936] [65157] [65170]
Panobinostat: (Major) Avoid coadministration of chloroquine with panobinostat due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has also been reported
with panobinostat. [28229] [28230] [28231] [29758] [58821] [65157] [65170]
Pasireotide: (Major) Avoid coadministration of chloroquine with pasireotide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. QT prolongation has occurred with
pasireotide at therapeutic and supra-therapeutic doses. [28229] [28230] [28231] [29758] [65157] [65170]
Pazopanib: (Major) Avoid coadministration of chloroquine with pazopanib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Pazopanib has also been reported to
prolong the QT interval. [28229] [28230] [28231] [29758] [37098] [65157] [65170]
Peginterferon Alfa-2a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is
an increased risk of retinal toxicity. [29758] [47391]
Peginterferon Alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is
an increased risk of retinal toxicity. [29758] [47391]
Peginterferon beta-1a: (Moderate) Concurrent use of chloroquine and interferons is not recommended as there is
an increased risk of retinal toxicity. [29758] [47391]
Penicillamine: (Major) Do not use penicillamine concurrently with antimalarials due to an increased risk of
severe hematologic and renal adverse reactions. [28834]
Penicillin G Benzathine; Penicillin G Procaine: (Moderate) Coadministration of penicillin G procaine with
oxidizing agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor
patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If
methemoglobinemia occurs or is suspected, discontinue penicillin G procaine and any other oxidizing agents.
Depending on the severity of symptoms, patients may respond to supportive care; more severe symptoms may
require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [31217]
Penicillin G Procaine: (Moderate) Coadministration of penicillin G procaine with oxidizing agents, such as
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is
suspected, discontinue penicillin G procaine and any other oxidizing agents. Depending on the severity of
symptoms, patients may respond to supportive care; more severe symptoms may require treatment with
methylene blue, exchange transfusion, or hyperbaric oxygen. [31217]
Pentamidine: (Major) Avoid coadministration of chloroquine with pentamidine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Systemic pentamidine has also been
associated with QT prolongation. [23620] [23778] [28229] [28230] [28231] [28419] [28879] [29758] [65157] [65170]
Perphenazine: (Major) Avoid coadministration of chloroquine with perphenazine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Perphenazine is associated with a
possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
Perphenazine; Amitriptyline: (Major) Avoid coadministration of chloroquine with perphenazine due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Perphenazine
is associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
(Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Phenobarbital: (Moderate) Coadministration of chloroquine and phenobarbital may decrease exposure of
chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and phenobarbital
is a strong CYP3A4 inducer. [65210] [65237] [65239]
Phenylephrine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Promethazine
is associated with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] 
[65170]
Phenytoin: (Moderate) Coadministration of chloroquine and phenytoin may decrease exposure of chloroquine
which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and phenytoin is a strong
CYP3A4 inducer. [65210] [65237] [65239]
Pimavanserin: (Major) Avoid coadministration of chloroquine with pimavanserin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Pimavanserin also prolongs the QT
interval. [28229] [28230] [28231] [29758] [60748] [65157] [65170]
Pimozide: (Severe) Coadministration of chloroquine with pimozide is contraindicated due to the increased risk
of QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes
(TdP); the risk of QT prolongation is increased with higher chloroquine doses. Pimozide is associated with a
well-established risk of QT prolongation and TdP. [28225] [28229] [28230] [28231] [29758] [43463] [65170]
Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Pirbuterol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28229] 
[28532] [29758] [49951] [51793] [59321] [65157] [65170]
Pitolisant: (Major) Avoid coadministration of chloroquine with pitolisant due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Pitolisant also prolongs the QT interval. 
[28229] [28230] [28231] [29758] [64562] [65157] [65170]
Ponatinib: (Moderate) Concurrent use of chloroquine and ponatinib is not recommended as there is an increased
risk of retinal toxicity. [29758] [52603]
Posaconazole: (Major) Avoid coadministration of chloroquine with posaconazole due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Posaconazole has been associated with
QT prolongation and TdP. [28229] [28230] [28231] [29758] [32723] [65157] [65170]
Pramlintide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including pramlintide, are coadministered. A decreased dose of the antidiabetic agent may be necessary
as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic
agent. [29758]
Praziquantel: (Minor) Concomitant administration of chloroquine and praziquantel can reduce praziquantel
bioavailability and maximum serum concentrations. The mechanism of the interaction is not certain. Clinicians
should be alert to the possibility of praziquantel failure if chloroquine is used. [27846] [29758]
Prilocaine: (Moderate) Coadministration of prilocaine with oxidizing agents, such as chloroquine, may increase
the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
prilocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [29064]
Prilocaine; Epinephrine: (Moderate) Coadministration of prilocaine with oxidizing agents, such as chloroquine,
may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
prilocaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [29064]
Primaquine: (Major) Avoid coadministration of chloroquine with primaquine due to the increased risk of QT
prolongation or other toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Primaquine
may also prolong the QT interval. [28229] [28230] [28231] [29758] [41984] [65157] [65170]
Procainamide: (Major) Avoid coadministration of chloroquine with procainamide due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Procainamide is associated with a well-
established risk of QT prolongation and TdP. [28229] [28230] [28231] [29758] [65157] [65170]
Prochlorperazine: (Major) Avoid coadministration of chloroquine with prochlorperazine due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Prochlorperazine is
associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Promethazine is associated with a
possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170]
Propafenone: (Major) Avoid coadministration of chloroquine with propafenone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Propafenone is a Class IC antiarrhythmic
which increases the QT interval, but largely due to prolongation of the QRS interval. [28229] [28230] [28231] 
[28287] [29758] [65157] [65170]
Protriptyline: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Quetiapine: (Major) Avoid coadministration of chloroquine with quetiapine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Limited data, including some case
reports, suggest that quetiapine may be associated with a significant prolongation of the QTc interval in rare
instances. [28229] [28230] [28231] [29118] [29758] [33068] [33072] [33074] [65157] [65170]
Quinidine: (Major) Avoid coadministration of chloroquine with quinidine due to the increased risk of QT
prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinidine
administration is also associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] [42280] [47357] 
[65157] [65170]
Quinine: (Major) Avoid coadministration of chloroquine with quinine due to the increased risk of QT
prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinine has
been associated with QT prolongation and rare cases of TdP. [28229] [28230] [28231] [29758] [31403] [65157] 
[65170]
Rabies Vaccine: (Major) If administered concurrently, antimalarials can impair the immunologic response to the
rabies vaccine, thereby, decreasing its protective effect. If possible, administration of antimalarials should be
avoided during use of the rabies vaccine for postexposure prophylaxis. When antimalarials must be administered
to persons also receiving the rabies vaccine for postexposure prophylaxis, a serum rabies antibody titer should be
obtained on day 14 (day of the 4th vaccination) to ensure an acceptable antibody response has been induced. 
[40848] [40849]
Ranolazine: (Major) Avoid coadministration of chloroquine with ranolazine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Ranolazine is associated with dose- and
plasma concentration-related increases in the QTc interval. [28229] [28230] [28231] [29758] [31938] [65157] [65170]
Regular Insulin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Regular Insulin; Isophane Insulin (NPH): (Major) Careful monitoring of blood glucose is recommended when
chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Repaglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Ribociclib: (Major) Avoid coadministration of chloroquine with ribociclib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Ribociclib has been shown to prolong
the QT interval in a concentration-dependent manner. [28229] [28230] [28231] [29758] [61816] [65157] [65170]
Ribociclib; Letrozole: (Major) Avoid coadministration of chloroquine with ribociclib due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Ribociclib has been
shown to prolong the QT interval in a concentration-dependent manner. [28229] [28230] [28231] [29758] [61816] 
[65157] [65170]
Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75
to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170]
Risperidone: (Major) Avoid coadministration of chloroquine with risperidone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Risperidone has been associated with a
possible risk for QT prolongation and/or TdP, primarily in the overdose setting. [22256] [28229] [28414] [29758] 
[59321] [65157] [65170]
Romidepsin: (Major) Avoid coadministration of chloroquine with romidepsin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Romidepsin has been reported to
prolong the QT interval. [28229] [28230] [28231] [29758] [37292] [65157] [65170]
Ropivacaine: (Moderate) Coadministration of ropivacaine with oxidizing agents, such as chloroquine, may
increase the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
ropivacaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [52330]
Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Salmeterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting beta-agonists.. 
[28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Saquinavir: (Major) Avoid coadministration of chloroquine with saquinavir boosted with ritonavir due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Saquinavir
boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for
serious arrhythmias such as TdP. [28229] [28230] [28231] [28995] [29758] [65157] [65170]
Saxagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Semaglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Sertraline: (Major) Avoid coadministration of chloroquine with sertraline due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. The risk of sertraline-induced QT
prolongation is generally considered to be low in clinical practice. Its effect on QTc interval is minimal
(typically less than 5 msec), and the drug has been used safely in patients with cardiac disease (e.g., recent
myocardial infarction, unstable angina, chronic heart failure). [28229] [28343] [29758] [64391] [64392] [64394] 
[64396] [65157] [65170]
Sevoflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics
are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] 
[59321] [65157] [65170]
SGLT2 Inhibitors: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Short-acting beta-agonists: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-
agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Simvastatin; Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly
with chloroquine and an antidiabetic agent. [29758]
Siponimod: (Major) Avoid coadministration of chloroquine with siponimod due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Siponimod therapy prolonged the QT
interval at recommended doses in a clinical study. [28229] [28230] [28231] [29758] [64031] [65157] [65170]
Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and
antacids at least 4 hours apart. [29758] [30284] [30285]
Solifenacin: (Major) Avoid coadministration of chloroquine with solifenacin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Solifenacin has been associated with
dose-dependent prolongation of the QT interval. TdP has been reported with postmarketing use, although
causality was not determined. [28229] [28230] [28231] [29758] [30515] [65157] [65170]
Sorafenib: (Major) Avoid coadministration of chloroquine with sorafenib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. An interruption or discontinuation of sorafenib therapy may be necessary if QT prolongation occurs.
Sorafenib has been associated with QT prolongation. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses [28229] [28230] [28231] [29758] [31832] [65157] [65170]
Sotalol: (Major) Avoid coadministration of chloroquine with sotalol due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Sotalol administration is associated with
QT prolongation and TdP. Proarrhythmic events should be anticipated after initiation of therapy and after each
upward dosage adjustment. [28229] [28230] [28231] [28234] [29758] [65157] [65170]
Succinylcholine: (Moderate) Chloroquine may enhance the neuromuscular blocking action of succinylcholine. 
[42039]
Sulfonylureas: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Sunitinib: (Major) Avoid coadministration of chloroquine with sunitinib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Sunitinib can also prolong the QT
interval. [28229] [28230] [28231] [29758] [65157] [65170]
Tacrolimus: (Major) Avoid coadministration of chloroquine with tacrolimus due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Tacrolimus may prolong the QT interval
and cause TdP. [28229] [28230] [28231] [28611] [29758] [55401] [60497] [65157] [65170]
Tamoxifen: (Major) Avoid coadministration of chloroquine with tamoxifen due to the increased risk of QT
prolongation and retinal toxicity. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Tamoxifen has
been reported to prolong the QT interval, usually in overdose or when used in high doses. Rare case reports of
QT prolongation have also been described when tamoxifen is used at lower doses. [28229] [28230] [28231] [29758] 
[61872] [63589] [65157] [65170]
Telavancin: (Major) Avoid coadministration of chloroquine with telavancin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Telavancin has also been associated with
QT prolongation. [28229] [28230] [28231] [29758] [36615] [65157] [65170]
Telbivudine: (Minor) Monitor patients for signs or symptoms of unexplained muscle pain, tenderness, or
weakness during concomitant treatment with chloroquine and telbivudine. Interrupt telbivudine therapy if
myopathy is suspected and discontinue telbivudine if myopathy is confirmed. It is unknown if the risk of
myopathy during treatment with telbivudine is increased with coadministration of other drugs associated with
myopathy, like chloroquine. [32827]
Telithromycin: (Major) Avoid coadministration of chloroquine with telithromycin due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Telithromycin is also
associated with QT prolongation and TdP. [28156] [28229] [28230] [28231] [29758] [65157] [65170]
Terbutaline: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to the increased
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists may be
associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be
more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28229] 
[28532] [29758] [49951] [51793] [59321] [65157] [65170]
Tetrabenazine: (Major) Avoid coadministration of chloroquine with tetrabenazine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Tetrabenazine causes a small increase in
the corrected QT interval (QTc). [28229] [28230] [28231] [29758] [34389] [65157] [65170]
Tetracaine: (Moderate) Coadministration of tetracaine with oxidizing agents, such as chloroquine, may increase
the risk of developing methemoglobinemia. Monitor patients closely for signs and symptoms of
methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue
tetracaine and any other oxidizing agents. Depending on the severity of symptoms, patients may respond to
supportive care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or
hyperbaric oxygen. [31353]
Thiazolidinediones: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic
agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with
chloroquine and an antidiabetic agent. [29758]
Thioridazine: (Severe) Coadministration of chloroquine with thioridazine is contraindicated due to the increased
risk of QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Thioridazine is associated
with a well-established risk of QT prolongation and TdP. [28225] [28229] [28230] [28231] [28293] [29758] [65170]
Tiotropium; Olodaterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Tolazamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Tolbutamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and antidiabetic
agents, including the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Tolterodine: (Major) Avoid coadministration of chloroquine with tolterodine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Tolterodine has been associated with
dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. [28229] [28230] 
[28231] [29758] [31112] [65157] [65170]
Toremifene: (Major) Avoid coadministration of chloroquine with toremifene due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Toremifene has been shown to prolong
the QTc interval in a dose- and concentration-related manner. [28229] [28230] [28231] [28822] [29758] [65157] 
[65170]
Trametinib: (Moderate) Concurrent use of chloroquine and trametinib is not recommended as there is an
increased risk of retinal toxicity. [29758] [60372]
Trazodone: (Major) Avoid coadministration of chloroquine with trazodone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Trazodone can prolong the QT/QTc
interval at therapeutic doses. In addition, there are postmarketing reports of TdP. [28229] [28230] [28231] [29758] 
[38831] [63609] [65157] [65170]
Tricyclic antidepressants: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs)
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine
doses. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the
QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). 
[28225] [28229] [28230] [28231] [28415] [28416] [29758] [65157] [65170]
Trifluoperazine: (Major) Avoid coadministration of chloroquine with trifluoperazine due to the increased risk of
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Trifluoperazine is
associated with a possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
Trimipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval,
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Triptorelin: (Major) Avoid coadministration of chloroquine with triptorelin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Androgen deprivation therapy (i.e.,
triptorelin) may prolong the QT interval. [28229] [28230] [28231] [29758] [45411] [65157] [65170]
Ultralente Insulin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic agent may be
necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an
antidiabetic agent. [29758]
Umeclidinium; Vilanterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs,
and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and
torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-agonists
may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher
doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval.
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared to short-acting
beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Vandetanib: (Major) Avoid coadministration of chloroquine with vandetanib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. An interruption of vandetanib therapy or dose reduction may be necessary for QT prolongation.
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT
prolongation is increased with higher chloroquine doses. Vandetanib can prolong the QT interval in a
concentration-dependent manner; TdP and sudden death have been reported in patients receiving vandetanib. 
[28229] [28230] [28231] [29758] [43901] [65157] [65170]
Vardenafil: (Major) Avoid coadministration of chloroquine with vardenafil due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Vardenafil is associated with QT
prolongation. Both therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval. 
[28216] [28229] [29758] [41124] [59321] [65157] [65170]
Vemurafenib: (Major) Avoid coadministration of chloroquine with vemurafenib due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Vemurafenib has also been associated
with QT prolongation. [28229] [28230] [28231] [29758] [45335] [59321] [65157] [65170]
Venlafaxine: (Major) Avoid coadministration of chloroquine with venlafaxine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Venlafaxine administration is associated
with a possible risk of QT prolongation; TdP has been reported with postmarketing use. [28229] [28230] [28231] 
[29758] [33715] [65157] [65170]
Vigabatrin: (Major) Vigabatrin should not be used with chloroquine due to potential retinal toxicity associated
with both drugs, unless the benefits of treatment clearly outweigh the risks. [29758] [36250]
Voriconazole: (Major) Avoid coadministration of chloroquine with voriconazole due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Voriconazole has been associated with
QT prolongation and rare cases of TdP. [28158] [28229] [28230] [28231] [29758] [65157] [65170]
Vorinostat: (Major) Avoid coadministration of chloroquine with vorinostat due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Vorinostat therapy is also associated
with a risk of QT prolongation. [28229] [28230] [28231] [29758] [32789] [65157] [65170]
Ziprasidone: (Major) Avoid coadministration of chloroquine with ziprasidone due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP);
the risk of QT prolongation is increased with higher chloroquine doses. Clinical trial data indicate that
ziprasidone causes QT prolongation; there are postmarketing reports of TdP in patients with multiple
confounding factors. [28229] [28230] [28231] [28233] [29758] [65157] [65170]
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64576 – Xenleta (lefamulin) package insert. Dublin, Ireland: Nabriva Therapeutics US, Inc.; 2019 Aug.
64969 – Bynfezia Pen (octreotide acetate) injection package insert. Cranbury, NJ: Sun Pharmaceutical
Industries, Inc; 2020 Jan.
65098 – Isturisa (osilodrostat) tablet package insert. Lebanon, NJ: Recordati Rare Disease, Inc.; 2020 Mar.
65157 – CredibleMeds. COVID-19 experimental therapies and TdP risk. Available on the World Wide Web at
http://https://crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-risk. Accessed March 23, 2020.
65170 – Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and
circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19
[published online ahead of print, March 25, 2020]. Mayo Clin Proc 2020;95.
65210 – University of Liverpool. COVID-19 Drug Interactions. Retrived April 6, 2020. Available on the World
Wide Web at https://www.covid19-druginteractions.org/.
65237 – Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry
screening assay. Anti-Cancer Drugs 1996;7:568-578.
65239 – Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: Identification of CYP2C8,
CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos
2003;31:748-754.
Monitoring Parameters
blood glucose
CBC
ECG
glucose-6-phosphate dehydrogenase (G6PD) activity
ophthalmologic exam
IV Compatibility of Chloroquine with:
Legend
 = Compatible
 = Incompatible
 = Results uncertain, variable or dependent on conditions
ND = No Data Available
From Trissel's 2™ Clinical Pharmaceutics Database 
 Admixture Syringe Y-Site Administration For Dilution
Normal saline- Sodium chloride 0.9% ND ND ND
Promethazine hydrochloride ND ND
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US Drug Names
Aralen
Global Drug names
Argentina
Nivaquine - (Sanofi-Aventis)
Australia
Chlorquin - (Aspen)
Nivaquine - (Rhone-Poulenc Rorer)
Austria
Resochin - (Bayer)
Belgium
Nivaquine - (Sanofi)
Brazil
Clopirim - (Quimioterapica)
Diclokin - (Kinder)
Difosquin - (Vitamed)
Palux - (Biolab Sanus)
Quinacris - (Cristalia)
Canada
Aralen - (Sanofi Synthelabo)
Czech Republic
Delagil - (ICN)
Denmark
Malarex - (Actavis)
Finland
Heliopar - (Orion)
France
Nivaquine - (Sanofi-Aventis)
Nopalu - (Pharmacie Centrale des Armees)
Savarine - (AstraZeneca)
Germany
Arthrabas - (Tosse)
Resochin - (Bayer)
Weimerquin - (Biokanol)
Greece
Avloclor - (IFET)
Demoquine - (Demo)
Savarine - (IFET (ΙΦΕΤ))
Hong Kong
Chlorocin - (Deltapharm)
Chlorquin - (Fisons)
Syncoquin - (Synco)
Hungary
Delagil - (PharmaSwiss)
India
Bitaquine - (Bombay Tablet)
Cadiquin - (Zydus)
Chlorolex - (Lexica)
Clokit - (Indoco)
Cloquin - (Indoco)
C-Quin - (Ikon)
Emquin - (Merck)
E-Vivax - (Themis Medicare)
Idiquin - (Indian Drugs)
Ingaquine - (Inga)
Jagquin - (Jagsonpal)
La-Quin - (Stadmed)
Lariago - (Ipca)
Larover - (Aglowmed)
Malaquin - (PC India)
Maliago - (Cipla)
Maligon - (Unijules)
Malswift - (Ind-Swift)
Melubrin - (Ranbaxy)
Neoquine - (Neon)
Nivaquine-P - (Piramal)
Paraquin - (Shreya)
Resochin - (Bayer)
Indonesia
Avloclor - (AstraZeneca)
Malarex - (Actavis)
Mexaquin - (Konimex)
Resochin - (Bayer)
Riboquin - (Dexa)
Ireland
Avloclor - (AstraZeneca)
Nivaquine - (Rhone-Poulenc Rorer)
Israel
Aralen - (Sanofi Winthrop)
Avloclor - (Zeneca)
Italy
Dichinalex - (Recordati)
Mexico
Aralen - (Sanofi-Aventis)
Klorokin - (Zerboni)
Maclorex - (Alpharma)
Paluken - (Kener)
Netherlands
Nivaquine - (Sanofi-Aventis)
New Zealand
Chlorquin - (Healthcare Logistics)
Nivaquine - (Aventis)
Philippines
Aralen - (Sanofi Synthelabo)
Chlorofoz - (Am-Europharma)
Chloromax - (Oboi)
Clorkin - (Doctors)
Poland
Arechin - (Polfa Pabianice)
Portugal
Resochina - (BayHealth)
Russian Federation
Delagil - (ICN)
Singapore
Avloclor - (AstraZeneca)
Malarex - (Danone Dumex)
South Africa
Anoclor - (Rolab)
Daraclor - (Glaxo Wellcome)
Daramal - (GSK)
Daramal-Paludrine - (Zeneca)
Mirquin - (Mirren)
Nivaquine - (Winthrop)
Plasmoquine - (Medchem)
Promal - (Propan)
Spain
Cidanchin - (Cidan)
Resochin - (Kern)
Switzerland
Chlorochin - (Streuli)
Nivaquine - (Sanofi-Aventis)
Pharmaquine - (Pharma Plus)
Resochine - (Bayer)
Thailand
Chewoquine - (Chew)
Diroquine - (Atlantic)
Genocin - (General Drugs)
Malacin - (ANB)
Maliaquine - (Sriprasit)
Nitaquin - (Utopian)
P-Roquine - (PP Lab)
Sinmoquin - (SSP)
Turkey
Kutlu - (Keymen)
Ukraine
Delagil - (Meda)
United Kingdom
Avloclor - (Alliance)
Malarivon - (Wallace Mfg Chem.)
Malaviron - (Wallace Mfg Chem.)
Nivaquine - (Sanofi-Aventis)
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